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Abstract 
Transgenic plants are attractive bioreactors for the production and storage of 
pharmaceutical recombinant proteins. Recombinant proteins must reach specific 
plant compartments via distinct transport pathways for their stable accumulation 
and specific modifications. In this study, I test the feasibility of using transgenic 
suspension tobacco BY-2 cells as bioreactors to produce a human lysosomal 
enzyme a-iduronidase (IDUA). Towards this goal, I have generated IDUA 
antibodies using either E. cc>/z-derived recombinant IDUA or synthetic peptides as 
antigens. Western blot analysis demonstrated that two of the IDUA antibodies 
specifically detected IDUA protein with little cross-reactivity with proteins from 
wild type tobacco BY-2 cells. In addition, I have generated transgenic BY-2 cell 
lines expressing various IDUA fusions with specific targeting sequences that 
would direct IDUA to distinct compartments via distinct transport pathways for 
accumulation and modification. IDUA fusions with a plant signal peptide 
expressing in transgenic BY-2 cells showed detectable IDUA inside the cells or in 
cultured media. The long term goal of this project is to produce and purify 
bioactive plant cell-derived human IDUA for enzyme replacement therapy as well 
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1.1 Human a-L-iduronidase (hIDUA) 
1.1.1 Lysosomal storage disease 
a-L-iduronidase (IDUA) is one of the human lysosomal enzymes. Its gene is 
located in chromosome 4pl6.3 (Scott et al, 1990) that has coding sequence of 1962 
bps. The gene encodes 653 amino acids including a signal peptide of 26 amino acids. 
The function of IDUA is to act as one of the hydro lytic enzymes in the 
sequential breakdown of the glycosaminoglycan (GAG) including heparan sufate and 
dermatan sulfate (Neiifeld et al., 1975; Dorfman and Matalon, 1976). GAG is long 
unbranched polysaccharides with repeating disaccharide unit. GAG found in all types 
of connective tissues especially in the cell surface and extracellular matrix. The high 
viscosity of GAG made it as a lubricating fluid in the joints, while its rigidity is 
suitable for maintaining structural of cells, tissues, and organs. Normally, GAG is 
degraded in lysosomes by a collection of lysosomal enzymes. However，if a person 
lack sufficient a-iduronidase, GAG will be accumulated in the lysosomes and thus all 
the body organs. This results in lysosomal storage disorder mucopolysaccharidosis 
type I (MPS I), which is formerly called Hurler, Hurler-Scheie, and Scheie 
syndromes. MPS I is an autosomal recessive inheritance disease (Hers, 1965) which 
affects multiple tissues and organs including respiratory, connective tissue, 
cardiovascular, gastrointestinal, ocular, neurologic and skeletal (Hopwood and 
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Morris, 1990). There are a wild range of symptoms ranging from severe to mild 
including mental retardation, enlargement of organs, corneal clouding, joint stiffness, 
and early death (Neufeld and Muenzer, 1995). Although MPS I is quite rare (estimate 
incidence 1:100,000), it can lead to severe morbidity and early mortality. 
V 
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1.1.2 Treatments of MPS I 
Nowadays, there are several available treatments of MPS I but they are either 
palliative or having high risk. These include risk bearing bone marrow and umbilical 
cord blood transplantation, that may be an option for severe MPS I patients. The 
whole blood system of the patients is replaced to restore IDUA synthesis. The other 
safer option is enzyme replacement therapy via injecting the deficient enzyme 
intravenously to the patients regularly though out the whole life. A commercial IDUA 
enzyme in the market (called Aldurazyme®) has been approved in the United States 
and Europe. Aldurazyme® is derived from the Chinese Hamster Ovary cells (CHO 
cells) that has been successfully tested on canine model to normalize IDUA level and 
remediate symptoms (Shull et al., 1994). Clinical trials also shown effectiveness in 
human (Wraith, et al., 2001). However, Aldurazyme® is very expensive. For a person 
of 40 to 80 kg, he or she will need about 240,000 to 480, 000 US dollars to purchase 
this enzyme for his or her life long therapy. In addition, potential problems exist 
including cost of scaling up the enzyme production and risk of contamination by 
animal virus. 
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1.2 Plant cells as bioreactors 
Several different expression systems can be used to produce recombinant 
proteins in the field of molecular biotechnology. Each expression systems has its 
strength and weakness. For example, the prokaryotic microorganism like Escherichia 
coli. (E. coil) is the simplest and sophisticated expression system but it does not have 
the ability for glycosylation as that of higher organisms. The eukaryotic 
microorganism like yeast is more closely related to animal, but it may also have 
different glycosylation pattern. Mammalian cell culture can produce exact human 
recombinant protein but it has .the risk of pathogenic infection and high cost of 
scaling up. 
To solve these problems, the use of plant as bioreactor to produce heterologous 
proteins for pharmaceutical and industrial uses has received increasing attention in 
the field of molecular biotechnology. Plant is higher eukaroyote and thus capable of 
producing proteins with similar post-translational modifications to human proteins. 
Plant is also safe because it is not an infectious agent to human and animals. Plants 
have been successfully used to produce antibodies and recombinant proteins (Hiatt et 
al., 1989; During et al., 1990; Whitelam et al., 1994; Conrad and Fiedler, 1998; 
Larrick et al., 1998; Zeitlin et al., 1998). Using plant cell cultures as bioreactors have 
certain advantages over whole plants, including precious control and short 
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production cycle, consistent quality and yield, and free of pest, agrochemicals and 
fertilizers (Hellwig et al., 2004). Most importantly, isolation and purification of 
recombinant proteins from culture cells or from culture media would be much easier 
and more cost effective (Fischer et al, 1999b; Fischer et al., 1999c; Doran, 2000; 
Schillberg et al., 2003) when the expressed protein is secreted outside the cells. 
Examples of proteins produced in plant cells include immunoglobulins (Drossard et 
al., 1997; Fischer tt al, 1999a) and interleukin (Magnuson et al., 1998; Kwon et al., 
2003). In particularly when the recombinant proteins are produced for clinical use, 
cell culture can provide sterile and controllable production conditions and easy 
purification procedures (Fischer et al., 1999b). Research had shown that recombinant 
human interlukin secreted to tobacco suspension culture were biological active 
(Magnuson et al., 1998). 
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1.3 The Plant secretary pathway 
Recombinant proteins produced in plant must be correctly target to its final 
destination for stable accumulation. Plant cells contain two functionally distinct 
vacuoles: lytic vacuole (LV) and protein storage vacuole (PSV) (Okita and Rogers, 
1996; Neuhaus and Rogers, 1998; Jiang and Rogers, 1999). LV is similar to 
lysosome in animal but PSV is unique in plant cell. Proteins synthesized in 
endoplasmic reticulum (ER) are transported by COPII vesicles to Golgi (Shimada et 
al., 1997). From Golgi, proteins with vacuolar sorting determinants (VSDs) are 
recognized by vacuolar sorting receptor (VSR) protein at trans Golgi (Okita and 
Rogers, 1996) and transported to vacuoles. While those without VSDs are secreted to 
the plasma membrane and then to the cell exterior (Denecke et al, 1990). Protease 
that are recognized by VSR at late Golgi are packed into clathrin coated vesicles 
(CCV) and transported to the lytic prevacuolar compartment (lytic PVC) and then to 
the LV (Paris et al., 1997). On the other hand, storage proteins are transported to the 
PSV via two different vesicular transport pathways: from ER via Golgi apparatus to 
PSV, or directly transport from ER to PSV bypassing Golgi apparatus. For the 
Golgi-dependent pathway, storage proteins from ER are transported by dense vesicle 
(DV) to prevacuolar compartment and then to PSV in pea (Robinson et al, 1998). 
For the Golgi-independent pathway, storage proteins from ER are transported 
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directly by precursor-accumulating vesicles (PAC) to PSV in pumpkin seeds 
(Hara-Nishimura et al., 1998) (Figure 1.1). 
G o i q i S e c r e t e o u t s i d e I 
PVC 




Figure 1.1 Plant vesicular transport pathways. 
Four transport routes of soluble proteins synthesized in endoplasmic reticulum (ER) 
to lytic vacuole and protein storage vacuole or secrete out of the cell. 
1. Clathrin coated vesicle (CCV) carries protease via Golgi to the lytic prevacuolar 
compartment (lytic PVC) and then lytic vacuole (LV). 
2. Dense vesicle (DV) carries seed-type storage protein via Golgi to the protein 
storage vacuole (PSV). 
3. The third route is direct ER to PSV pathway, proteins carry by the precursor 
accumulating vesicle bypass the Golgi and directly go to PSV. 
4. Protein synthesized without any targeting signal will be secreted outside the cell. 
8 
1.3.1 Transport of soluble proteins 
Soluble proteins are transported from ER to LV or PSV if they contain VSD. 
There are three types of VSDs in plant cells including N-terminal propeptide 
(Matsuoka and Nakamura, 1991; Holwerda et al, 1992), C-terminal propeptide 
(Bednarek et al, 1990; Neuhaus et al., 1991), and internal determinants within 
proteins (Saalbach et al., 1991; Chrispeels and Raikhel, 1992). 
Propeptides are peptides that are removed post-translationally in the prevacuolar 
compartment or vacuole. N-terminal propeptide (NTPP) shares a conserved amino 
acid NPIR motif at their N-terminal. NTPP are found in vacuolar cystein protease 
aleurain in barley (Holwerda et al, 1992) and vacuolar storage protein sporamin in 
sweet potato (Neuhaus and Rogers, 1998). These proteins are recognized by vacuolar 
sorting receptor (VSR) and transported to LV. C-terminal propeptide (CTPP) does 
not share conserved sequence in their C-terminal but usually have an enriched 
sequence of hydrophobic amino acids (Dombrowski et al, 1993; Neuhaus et al, 
1994) and targets proteins to PSV. Internal determinants within proteins are found in 
castor bean ricin and targets to PSV (Vitale and Raikhel, 1999). 
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1.3.2 Transport of integral membrane proteins 
A reporter system was established to study traffic of 80-kDa binding protein 
(BP-80) (Jiang and Rogers, 1998), the obtained results demonstrated that the 
transmembrane domain (TMD) and cytoplasmic tail (CT) were essential for correct 
targeting of the reporter in plant cells. When a proaleurain that lacked of VSD was 
fused with BP-80 TMD and BP-80 CT and expressed in tobacco suspension culture 
cell，it transported through Golgi to lytic PVC and finally to LV. However, when the 
mutated proaleurain was fused with a BP-80 TMD and a-TIP CT, it transported 
directly from ER to PSV-like organelle in tobacco suspension cells. This construct 
was further expressed in transgenic tobacco plant and found that the protein was 
localized in the PSV crystalloid. These results indicated that BP-80 TMD and a-TIP 
CT can target proteins to PSV crystalloid or equivalent organelle via 
Golgi-independent pathway (Jiang and Rogers, 1998). 
Research making use of BP-80 TMD and a-TIP CT sequence had successfully 
expressed a YFP fusion protein in the PSV crystalloid of transgenic tobacco plant 
through direct ER to PSV pathway (Fung et al., 2005). This Golgi-independent 
pathway can avoid the unwanted plant-specific Golgi modification such as complex 
N-linked glycosylation to the recombinant proteins in plant bioreactors. 
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1.4 Differences between plant and human proteins 
PSV is unique in plant cells and abundant in the seed, which makes transgenic 
seed an attractive bioreactor for the production and storage of recombinant proteins. 
However, there are some differences between plant- and human-derived proteins. For 
example, complex plant-specific N-liiik glycosylation in plant Golgi, such as the 
addition of xylose, may be allergic to human. In addition, plant-derived recombinant 
glycoproteins lack the terminal galactose (Gal) and sialic acid (SA) residues that are 
normally found in human. Furthermore, plant lacks the mannose-6-phosphate (M6P) 
targeting system for lysosomal targeting of enzymes in mammalian cells. In enzyme 
replacement therapy, soluble recombinant lysosomal enzyme is taken up by human 
fibroblasts through M6P-receptor-mediated endocytosis and then targeted to 
lysosomes. Without M6P tag, the recombinant enzyme cannot be targeted to 
lysosomes and may either be degraded or secreted to the cell exterior through the 
secretary default pathway. 
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1.5 Reducing the differences between plant and human proteins 
We can reduce the differences between plant and human proteins by removing 
or bypassing the unwanted plant-specific N-link glycosylation. For example, proteins 
directly transported from the ER to PSV by precursor accumulating vesicles 
bypassing Golgi lacked Golgi-specific modifications. 
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1.6 Previous study: Expression of IDUA in transgenic tobacco plant 
Four chimeric recombinant human iduronidase (hIDUA) constructs were 
previously developed and expressed in transgenic tobacco plants (Figure 3.10). (i) 
SPp-IDUA is composed of proaleurain signal peptide lacking of VSD, followed by 
IDUA. (ii) SPi-IDUA is composed ofhIDUA signal peptide, followed by IDUA. (iii) 
SPp-IDUA-T7-526 is composed of proaleurain signal peptide lacking of VSD, 
followed by IDUA, T7 epitope tag, BP-80 TMD and a-TIP CT. (iv) 
SPi-IDUA-FLAG-526 is composed of hIDUA singal peptide, IDUA, FLAG epitope 
tag, BP-80 TMD and a-TIP CT. Construct (i) and (ii) are expected to be secreted out 
of the cell, while (iii) and (iv)are expected to localized at the PSV crystalloid. 
All the four constructs were successfully transformed into tobacco plants and 
show expression of IDUA cDNA at the transcriptional level by RT-PCR and 
Northern blot analysis. However, the expression of IDUA in transgenic seed was low 
and the localization of IDUA in transgenic seeds remained to be determined. In 
addition, the failure in detecting and localizing IDUA in transgenic tobacco seeds 
might also be due to low specificity of IDUA antibodies generated in the previously 
study. 
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1.7 Proj ect obj ectives 
The objective of this study was to test and use tobacco BY-2 cells as bioreactor 
to express and produce human IDUA. 
Specific objectives of this research include the followings: 
(1) To generate IDUA antibodies for detection of plant-derived IDUA in 
transgenic tobacco BY-2 cells. 
(2) To express IDUA fusions in transgenic tobacco BY-2 cells. 
(3) To study the subcellular localization of IDUA fusion in transgenic tobacco 
BY-2 cells. 
1.8 Long term significance 
The long term significance of this project is to produce and purify bioactive 
plant-derived IDUA to be used in enzyme replacement therapy and establish a 




Materials and Methods 
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2.1 Introduction 
IDUA antibodies were produced using either human a-iduronidase (hIDUA) 
synthetic peptides or E. co/z-derived recombinant hIDUA (rhIDUA) as antigens. The 
antibodies were affinity purified and used as a tool in the analysis of transgenic 
tobacco BY-2 cells. 
Four chimeric recombinant human a-iduronidase (hIDUA) constructs under the 
control of cauliflower mosaic virus 35S (CaMV35S) promoter and nopaline synthase 
(NOS) terminator were prepared (as shown in Figure 3.10 in Results). They were 
cloned into binary vector pBI12l and transformed into tobacco BY-2 cells by 
Agrobacterium-mQdiaiQd transformation. The expression of IDUA in transgenic BY-2 
cells was tested by genomic DNA PCR, total RNA RT PCR and western blot 
analysis. 













































































































































































































































































Most chemicals used were of reagent grade or molecular grade and purchased 
from Sigma or Bio-Rad unless otherwise specified. Restriction enzymes and other 
modifying enzymes for molecular biology experiments were obtained from New 
England Biolabs, Invitrogen and Promega unless otherwise specified. 
2.2.2 Plant materials 
Wild type tobacco BY-2 cells were provided from Prof. Jiang's laboratory 
(CUHK, Hong Kong). 
2.2.3 Plasmid vectors and bacterial strains 
The pGEM-T Vector System was purchased from Promega Biosciences. The 
pGEX-4T-l vector was purchased from Amersham Biosciences. pBI221 and pBI121 
vectors were provided by Prof. Jiang's laboratory (CUHK, Hong Kong). E. coli 
strain DH5a was purchased from Invitrogen to use as a host for pGEM-T, 
pGEX-4T-l, pBI221 and pBI121 vectors manipulation and maintenance. E. coli 
strain BL21 provided by Yun Shen (CUHK, Hong Kong) was used as a host for 
pGEX-4T-l vector manipulation and expression. Agrobacterium tumefaciens strain 
18 
LBA4404 from Prof. Jiang's laboratory was used as a host for tobacco BY-2 cells 
transformation. 
2.2.4 Human a-iduronidase (hIDUA) cDNA 
hIDUA cDNA (accession No. NM一000203 in PubMed) was kindly provided by 
Prof. L.A. Clarke (University of British Columbia, Canada). The hIDUA cDNA is 
1,962bps long and is bluntly ligated into the EcoRV site of plasmid pBluescriptll 
KS+. The clone is oriented with the hIDUA start codon on the T3 side i.e. Hindlll 
site of the pBluescriptll KS+ with an ampicillin-resistance gene inside. In addition, 
the sequence of this clone shares a point mutation and three single nucleotide 
polymorphisms (Scott et al, 1995) with the cDNA sequence in PubMed as listed in 
Table 2.1. 
Table 2.1 Differences between hIDUA cDNA clone used in this study and the 
sequence listed in PubMed with accession No. NM 000203. 
Oligonucleotide Difference Codon Number and Codon Change 
b p l 8 8 A t o C (CAGtoCCG) Codon 63: Gin to Pro (G63P) 
bp314GtoA (CGGtoCAG) Codon 105: Arg to Gin (R105Q) (Scott et al, 1991b) 
bp352TtoC (TTGtoCTG) Codon 118: Leu to Pro (LI 18) (Scott et al, 1991a) 
bp543 T to C (AAT to AAC) Codon 181: remains Asn (N181) (Scott etal, 1993) 
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2.2.5 Primers 
Primers used in this study are listed in table 2.2. They were synthesized by 
Integrated DNA Technologies. 
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Table 2.2 Primers used in this study. Underline indicates restriction cutting 
sites. 
Primers for cloning N-terminal and C-terminal IDUA for E. a?//-derived rhIDUA 
Constructs Primer Sequence (5，to 3，） Purpose 
N-IDUA: 1-F GGG GGA TCC GAG GCC CCG Forward primer to 
From 79 - CAC CTG GTG CAG amplify N-IDUA and 
1002 (924 bp) addition of BamHl 
cutting site 
1-R GGG CTC GAG TCA CAG TAG Reverse primer to 
CAG GTT CTG ATG CTG CGC amplify N-IDUA and 
addition of Xhol 
cutting site 
C-IDUA: 2-F GGG GGA TCC GCC AAC ACC Forward primer to 
From 1003 - ACC TCC GCC TTC C amplify C-IDUA and 
1962 (961 bp) addition of BamHl 
cutting site 
2-R GGG CTC GAG TCA TGG ATT Reverse primer to 
GCC CGG GGA TGG G amplify C-IDUA and 
addition of Xhol 
cutting site 
Sequencing primers for hIDUA in pBI221 
Primer Sequence (5，to 3，） Purpose 
35S Pro. TCC TTC GCA AGA CCC TTC CTC As forward primer 
Nos Ter. CAT CGC AAG ACC GGC AAC AGG As reverse primer 
1-F GGG GGA TCC GAG GCC CCG CAC CTG As forward primer 
GTG CAG 
ID964-F GTG GTG AAG GTC ATG GCG As forward primer 
ID594-F CCT GAA CTA CTA CGA TGC As forward primer 
ID1216-F TCG CAG GCC GGG ACC GTC As forward primer 
ID1722-R GCC CAC GTG TTC ATC CGA As reverse primer 
18S rRNA primers for RT-PCR  
Primer Sequence (5，to 3，) Purpose  
18S-F TCTATGGGTGGTGGTGCATGGCCGTTCTTAGTTGG As forward primer 
18S-R TTACCCGGGCCTGTCGGCCAAGGCTATAAACTCG As reverse primer 
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2.3 Methods 
2.3.1 Generation of IDUA antibodies 
To facilitate the detection and purification of plant-derived IDUA, IDUA 
antibodies were produced by injecting rabbits with either hIDUA synthetic 'peptides 
or E. co//-derived recombinant rhIDUA protein as antigens (Figure 2.2). 
1 26 
(A) Human IDUA | SP | Full length IDUA 
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(B) Eco//-derived rhIDUA | N-IDUA 
C-IDUA I 
335 653 
Antibody produced Bla, B1b B2a, B2b 
C + 1 ^ 151 481 500 577 M5 
(C) Synthetic peptides [Peptide l | |Peptide 2丨 [Peptide 3 
Antibody produced i a , IB 2A, 2B 3A, 3B 
Figure 2.2 The human IDUA and its antibodies. 
(A) Full-length human IDUA. SP: signal peptide, number indicates position of 
amino acid from start codon (1) to stop codon (653). 
(B) E. co//-derived recombinant rhIDUA and the identity of corresponding 
antibodies generated from this study. 
(C) Positions of synthetic peptides and the identity of their corresponding antibodies. 
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2.3.1.1 Synthetic peptide raised IDUA antibodies 
2.3.1.1.1 Design of synthetic peptides 
Three synthetic peptides contain 17 to 19 amino acids were designed from 
hIDUAbase on the following criteria: 
• The hydrophobicity plot of hIDUA 
• The hydrophilic region were chosen 
Theoretically, after protein folding, the hydrophilic portion is exposed on the 
exterior while the hydrophobic portion is in the interior. Amino acid sequences 
from the hydrophilic region were chosen to make synthetic peptides (Figure 2.3). If 
the antibody can recognize peptide of the hydrophilic side, it should also recognize 
the exterior of native hIDUA. 
• The hydrophobic amino acid content was kept under 50% 
As hydrophobicity affects peptide solubility, the hydrophobic amino acid 
content was kept below 50% to improve peptide solubility for immunizing rabbits. 
• Specificity of peptides 
The peptide sequence is specific towards hIDUA and not showing any 
similarity to tobacco proteins by BLAST search with green plant database. This 
step is to avoid newly generated antibody having cross-reactivity with the tobacco 
proteins with having similar peptide sequences. 
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• Avoid glycosylation site 
Since hIDUA contains at least six N-glycosylation sites, the synthetic peptides 
design should avoid these sites, because the epitope on these sites will be affected by 
the structure of N-glycans and thus affects antibody binding. 
^ QQ Hy-dropatliy index (I^e-Do olitt le, 1982) 
4. 00 _ 
3. 00 _ J 
1 . � � _ ! J J I j 1 I j 111 
-3.00 _ U Peptides Peptide 1 
-4.00 _ Peptide2 
- " � � 1 . . 1 1 1—— 
10 0 20 0 300 400 SOO 600 
Peptide 1: C-SASGJJFTDFEDKQQVTE (C + from 135 a.a. to 151 a.a.) 
Peptide 2: CSPDGEWRRLGRPVFPTAE (from 481 a.a. to 500 a.a.) 
Peptide 3: CLWTYUQFSQDGKAYTPV (from 577 a.a. to 595 a.a.) 
Figure 2.3 The hydrophobicity plot of full length hIDUA protein. 
Positive values in the y-axis indicate hydrophobicity of protein while negative 
values indicate hydrophilicity. Three synthetic peptides were chosen as antigens base 
on there hydrophilicity. The peptides were conjugated with carrier protein keyhole 
limpet (KLH) and used to immunize rabbits. A cysteine C residue was added or 
originally present at the N-terminal of each peptide for making affinity column. The 
amino acid sequences of synthetic peptides are shown in the diagram which also 
indicating their relative position in the full length IDUA protein, a.a.: amino acid. 
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2.3.1.1.2 Immunization of rabbits 
As the peptides are too small to induce immune response, they were conjugated 
with carrier protein keyhole limpet haemocyanin (KLH) and used to immunize 
rabbits as described (Tse et al, 2004). The purified rhIDUA protein was mixed with 
Freund's complete adjuvant (Sigma) for the first injection. In the consequence 
injection, Freund's incomplete adjuvant (Sigma) was used. A total of four injections 
using 200 |ig, 200 )ig, 100 j^ g and 100 \ig KLH-conjugated peptides respectively 
were performed in a biweekly basis in the Animal House of the Chinese University 
of Hong Kong. 
2.3.1.2 E. a?//-derived rhIDUA protein 
2.3.1.2.1 Cloning and expression of rhIDUA 
E. coli strain BL21 was used in the production of rhIDUA protein for 
immunizing rabbits. A 1,962bps full length IDUA (accession No. NM_000203 in 
PubMed) ligated in pBluescript II KS+ was kindly provided by Professor L.A. 
Clarke. Since the full length of hIDUA is too large for bacterial expression, it was 
divided into 2 portions -- the N-terminal (N-IDUA) and C-terminal (C-IDUA). The 
sequences of these two constructs are shown in Table 2.3. Primers used in the 
cloning of these 2 constructs are shown in table 2.2. BamHl and Xhol sites were 
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added to facilitate the cloning into pGEX-4T-l multiple cloning sites. Twenty-five 
microliter PGR reaction mix containing 0.5 |iL IDUA plasmid DNA, 2.5 juL 2mM 
dNTPs, 2.5 |iL lOx PGR buffer, 1.25 ^L 50uM MgCh，0.5 jiL forward primer, 0.5 
fiL reverse primer and 0.5 jiL Platinum Tag DNA polymerase (1 unit/f^L). The 
PGR condition was: 95°C for 3 mins, 94°C for 1.5mins, 70°C for 3 mins, 72°C for 
5 mins, 30 cycles of 94�C for 1.5 mins, 70�C for 2 mins, 72�C for 2 mins and 1 
cycle of 72�C for 10 mins. After PGR, the PGR products were resolved in 1% 
agarose gel and the target bands were cut and elute by DEAE paper as described in 
Sambrook and Russell (2001). The eluted DNA was ligated to PGEX T-vector and 
then transformed E. coli. strain DH5a. The clone was checked by restriction 
digestion and sequencing before transferring to pGEX-4T-l vector and expressed in 
E. coli strain BL21. Transformation and expression of rhIDUA was done according 
to manufacturer protocol. 
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Table 2.3 Nucleotide and amino acid sequences of E. coli-den\ed rhIDUA 
protein 
G S T t a a + N - t e r m i n a l I D U A n u c l e o t i d e s e q u e n c e 
ATG TCCCCTATAC TAGGTTATTG GAAAATTAAG GGCCTTGTGC 
AACCCACTCG ACTTCTTTTG GAATATCTTG AA6AAAAATA TGAAGAGCAT TTGTATGAGC GCGATGAAGG TGATAAAT6G CGAAACAAAA AGTTT6AATT 6G6TTTGGA6 TTTCCCAATC 
TTCCTTATTA TATTGATGGT GATGTTAAAT TAACACA6TC TATGGCCATC ATACGTTATA TAGCTGACAA GCACAACATG TTGGGT6GTT GTCCAAAAGA 6CGTGCA6AG ATTTCAATGC 
TTGAAGGAGC 6GTTTTGGAT ATTAGATACG GTGTTTCGAG AATTGCATAT A6TAAAGACT TTGAAACTCT CAAA6TTGAT TTTCTTAGCA AGCTACCTGA AATGCTGAAA ATGTTCGAAG ^ ^ ^ 
GST tag 
ATCGTTTATG TCATAAAACA TATTTAAATG GTGATCATGT AACCCATCCT GACTTCATGT TGTATGACGC TCTT6ATGTT GTTTTATACA TGGACCCAAT 6T6CCTGGAT GCGTTCCCAA 
AATTAGTTTG TTTTAAAAAA CGTATTGAAG CTATCCCACA AATTGATAAG TACTTGAAAT CCAGCAAGTA TATAGCATGG CCTTTGCAGG GCTGGCAAGC CACGTTTGGT GGTG6CGACC 
ATCCTCCAAA ATCG6ATCTG GTTCCGCGT6 6ATCC 
GA GGCCCCGCAC CTGGTGCAGG TGGACGCGGC CCGCGCGCTG TGGCCCCTGC 6GCGCTTCTG GA6GAGCACA G6CTTCTGCC CCCC6CTGCC ACACAGCCAG 
GCTGACCCGT ACGTCCTCAG CTGGGACCAG CAGCTCAACC TCGCCTATGT GGGCGCCGTC CCTCACCGCG GCATCAAGCA GGTCCGGACC CACTGGCT6C TGGAGCTTGT CACCACCAGG 
6GGTCCACTG GACAGGGCCT GA6CTACAAC TTCACCCACC TG6ACGGGTA CCTGGACCTT CTCAGG6AGA ACCAGCTCCT CCCAGGGTTT GAGCT6ATGG 6CAGC6CCTC GGGCCACTTC 
ACT6ACTTTG AGGACAAGCA GCAGGTGTTT GAGTGGAAGG ACTTGGTCTC CA6CCTGGCC AGGAGATACA TCGGTAGGTA CGGACTGGCG CATGTTTCCA AGTGGAACTT CGAGACGTGG N-IDUA 
AACGAGCCAG ACCACCACGA CTTTGACAAC GTCTCCATGA CCATGCAAGG CTTCCTGAAC TACTACGATG CCTGCTCGGA GGGTCTGCGC GCCGCCAGCC CCGCCCTGCG GCTGGGAGGC 刊 " 
CCCGGCGACT CCTTCCACAC CCCACC6CGA TCCCCGCTGA GCTGGGGCCT CCTGCGCCAC TGCCACGACG GTACCAACTT CTTCACTGGG GAGGCGGGCG TGCGGCTGGA CTACATCTCC ^ ^ ^ ^ ^ ^ ^ ^ b P ) 
CTCCACAGGA A6GGTGCGCG CAGCTCCATC TCCATCCTGG A6CAGGAGAA GGTCGTCGCG CAGCAGATCC GGCAGCTCTT CCCCAAGTTC GCGGACACCC CCATTTACAA C6ACGAGGCG 
6ACCCGCTGG TGGGCTGGTC CCTGCCACAG CCGTGGAGGG CG6ACGTGAC CTACGCGGCC ATG6TGGTGA AGGTCATCGC 6CAGCATCAG AACCTGCTAC TG TGA 
GST tag + N-terminal IDUA amino acid sequence 
pi = 5,48 
Mw = 64.26794 kDa (Calculated from Expasy) 
M e t S P I L G Y W K I K G L V Q P T R L L L E Y L E E K Y E E H L Y E R D E G D K W R N K K F E L G L E F P N L P 
Y Y I D G D V K L T Q S M e t A I I R Y I A D K H N M e t L G G C P K E R A E l S M e t L E G A V L D I R Y G V S R I A Y S 
K D F E T L K V D F L S K L P E M e t L K M e t F E D R L C H K T Y L N G D H V T H P D F M e t L Y D A L D V V L Y M e t 
D P M e t C L D A F P K L V C F K K R I E A I P Q I D K Y L K S S K Y I A W P L Q G W Q A T F G G G D H P P K S D L V 
P R G S E A P H L V Q V D A A R A L W P L R R F W R S T G F C P P L P H S Q A D P Y V L S W D Q Q L N L A Y V G A 
V P H R G I K Q V R T H W L L E L V T T R G S T G Q G L S Y N F T H L D G Y L D L L R E N Q L L P G F E L M e t G S 
A S G H F T D F E D K Q Q V F E W K D L V S S L A R R Y I G R Y G L A H V S K W N F E T W N E P D H H D F D N V 
S M e t T M e t Q G F L N Y Y D A C S E G L R A A S P A L R L G G P G D S F H T P P R S P L S W G L L R H C H D G T N 
F F T G E A G V R L D Y I S L H R K G A R S S 丨 S I L E Q E K V V A Q Q I R Q L F P K F A D T P I Y N D E A D P L V G 
W S L P Q P W R A D V T Y A A M e t V V K V I A Q H Q N L L L Stop 
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G S T tag + C - t e rmina l I D U A nucleot ide s e q u e n c e 
ATG T C C C C T A T A C T A G G T T A T T G 6 A A A A T T A A G G G C C T T G T G C 
A A C C C A C T C G A C T T C T T T T G G A A T A T C T T G A A G A A A A A T A T G A A G A G C A T T T G T A T G A G C Q C 6 A T G A A G G T 6 A T A A A T G G C G A A A C A A A A A G T T T G A A T T G G G T T T G G A G T T T C C C A A T C 
T T C C T T A T T A T A T T G A T G G T G A T G T T A A A T T A A C A C A G T C T A T G G C C A T C A T A C G T T A T A T A G C T G A C A A G C A C A A C A T 6 T T G G G T G 6 T T G T C C A A A A G A G C G T G C A G A G A T T T C A A T G C 
T T G A A G G A G C G G T T T T G G A T A T T A G A T A C G G T 6 T T T C G A G A A T T G C A T A T A 6 T A A A G A C T T T G A A A C T C T C A A A G T T G A T T T T C T T A G C A A G C T A C C T G A A A T G C T G A A A A T G T T C G A A G 
GST tag 
A T C G T T T A T G T C A T A A A A C A T A T T T A A A T G G T G A T C A T G T A A C C C A T C C T G A C T T C A T 6 T T G T A T G A C G C T C T T G A T G T T G T T T T A T A C A T G G A C C C A A T G T G C C T 6 G A T G C G T T C C C A A 
A A T T A G T T T G T T T T A A A A A A C G T A T T G A A G C T A T C C C A C A A A T T G A T A A G TACTTGAAAT C C A G C A A G T A T A T A G C A T G G C C T T T 6 C A G G G C T G G C A A 6 C C A C G T T T G G T G G T G 6 C G A C C 
A T C C T C C A A A A T C G G A T C T G G T T C C G C 6 T G 6 A T C C 
G C C A A C A C C A C C T C C G C C T T C C C C T A C G C G C T C C T G A G C A A C G A C A A T G C C T T C C T 6 A 6 C T A C C A C C C G C A C C C C T T C G C G C A 6 C G C A C G C T C A C C G C G C G C T T C C A G G T C A A C A A C A 
C C C G C C C G C C G C A C G T G C A G C T G T T G C G C A A G C C G G T G C T C A C G G C C A T G G G G C T 6 C T G G C G C T G C T G G A T G A G G A G C A 6 C T C T G G G C C G A A G T G T C G C A G G C C 6 G G A C C G T C C T G G A C A 
G C A A C C A C A C G G T G G G C G T C C T G G C C A G C G C C C A C C G C C C C C A G G G C C C G G C C G A C G C C T G G C G C 6 C C 6 C G G T G C T G A T C T A C G C 6 A G C G A C G A C A C C C G C G C C C A C C C C A A C C G C A G C G ^ I D U A ^ 
T C G C G G T 6 A C C C T 6 C G G C T G C G C G G G G T G C C C C C C G G C C C G G G C C T G 6 T C TACGTCAC6C G C T A C C T G G A C A A C G G G C T C T G C A G C C C C G A C G G C G A G T G G C G G C G C C T G G G C C G G C C C G „ , 
From 1003 -
T C T T C C C C A C G G C A G A G C A G T T C C G G C G C A T G C G C G C G G C T G A G G A C C C G G T G G C C G C G G C G C C C C G C C C C T T A C C C G C C G G C G G C C G C C T G A C C C T G C G C C C C G C G C T G CGGCTGCCGT , , 、 1962 (y61 bp) 
C G C T T T T G C T G 6 T G C A C G T G T G T G C G C G C C C C 6 A G A A 6 C C G C C C G G G C A G G T C A C G C G 6 C TCCGCGCCCT G C C C C T G A C C C A A G 6 G C A G C T G G T T C T 6 G T C T G G T C G G A T GAACACGTGG 
G C T C C A A G T G C C T G T G G A C A T A C G A G A T C C A G T T C T C T C A G G A C G G T A A G G C G T A C A C C C C G G T C A 6 C A G G A A G C C A T C G A C C T T C A A C C T C T T T G T G T T C A G C C C A G A C ACAGGTGCTG 
T C T C T G G C T C C T A C C G A G T T C G A G C C C T G G A C T A C T G G G C C C G A C C A G G C C C C T T C T C G G A C C C T G T G C C G T A C C T G G A 6 6 T C C C T G T G C C A A G A G G G C C C C C A T C C C C 6 GGCAATCCAT 
GA 
GST tag + C-terminal IDUA amino acid sequence 
PI 二 6.42 
Mw = 63.83 kDa (Calculated from Expasy) 
M e t S P I L G Y W K I K G L V Q P T R L L L E Y L E E K Y E E H L Y E R D E G D K W R N K K F E L G L E F P N L P 
Y Y I D G D V K L T Q S M e t A I I R Y I A D K H N M e t L G G C P K E R A E I S M e t L E G A V L D I R Y G V S R I A Y S 
K D F E T L K V D F L S K L P E M e t L K M e t F E D R L C H K T Y L N G D H V T H P D F M e t L Y D A L D V V L Y M e t 
D P M e t C L D A F P K L V C F K K R I E A l P Q I D K Y L K S S K Y l A W P L Q G W Q A T F G G G D H P P K S D L V 
P R G S A N T T S A F P Y A L L S N D N A F L S Y H P H P F A Q R T L T A R F Q V N N T R P P H V Q L L R K P V L T 
A M e t G L L A L L D E E Q L W A E V S Q A G T V L D S N H T V G V L A S A H R P Q G P A D A W R A A V L I Y A S D 
D T R A H P N R S V A V T L R L R G V P P G P G L V Y V T R Y L D N G L C S P D G E W R R L G R P V F P T A E Q F 
R R M e t R A A E D P V A A A P R P L P A G G R L T L R P A L R L P S L L L V H V C A R P E K P P G Q V T R L R A L P L 
T Q G Q L V L V W S D E H V G S K C L W T Y E I Q F S Q D G K A Y T P V S R K P S T F N L F V F S P D T G A V S G 
S Y R V R A L D Y W A R P G P F S D P V P Y L E V P V P R G P P S P G N P Stop 
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2.3.1.2.2 Western analysis of E. coli-den\ed rhIDUA 
The transformed BL21 bacteria cell was pelleted by centrifuging the growth 
medium. IX SDS sampling buffer was used to resuspend the pellet. The total 
bacteria lysate was boiled in 99�C for 10 min before resolving in SDS-PAGE. The 
gel was transferred to nitrocellulose membrane and detected by GST antibody (4 
fig/mL) (Amersham Bioscience) or IDUA antibody (4 |ig/mL) (gift from Dr. Todd C. 
Zankel, BioMarine Pharmaceutical Inc. USA). 
2.3.1.2.3 MS/MS analysis of rhIDUA protein 
Total bacteria lysate was boiled in 99。C for 10 min before resolving in 
SDS-PAGE. After coomassie blue staining, the target band was cut into smaller 
pieces with a surgical needle. Twenty microliter of 50% MeOH/50mM NH4HC03 
was added to immerse the excised protein sample and vortex for 1 to 3 min. The 
process was repeated for twice to ensure total destain of the protein spot. In-gel 
digestion was carried out by dehydrating the gel with 25 |uL acetonitrile (ACN) for 
10 min and repeated for 3 times. The gel was dried in speed vacuum for 2-5 min 
until the gel appeared "dust like". Then the gel was rehydrated with 7.5 jil trypsin 
enzyme in buffer (40 ng/pi trypsin in 50mM ammonium bicarbonate) and incubated 
on ice for 30 min. Extra buffer solution (50mM ammonium bicarbonate) was added 
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to cover the hydrated gel piece before performing overnight digestion at 30�C. The 
digested protein was extracted by adding 20 |liL 50 mM ammonium bicarbonate and 
sonicate for 10 min. Then add 20 )iL ACN: 5% TFA (1:1) and sonicate for 10 min. 
The supernatant was transferred to a new tube. The extraction was repeated for two 
times and the supernatant was combined. Finally 10 [iL ACN was added and 
sonicated for 10 min. The supernatant was collected and combined and dried with 
speed vacuum for 2 hrs until dryness. 
Before loading to MS/MS machine (ABI 4700)，desalting of the digested 
sample was performed by ZipTip®. The vaccum-dried sample was resuspended in 10 
\iL 0.1% trifluoracetic acid (TFA). The ZipTip® was wetted 2 times by aspirated 10 
[iL wetting solution (50% ACN) into the tip and dispensed to waste. The ZipTip® 
was equilibrated 2 times by aspirating 10 |LIL equilibrium solution (0.1% TFA) into 
the tip and dispense to waste. The sample was then bonded into ZipTip® by 
aspirating and dispensing 10 cycles in the eppendorf tube. The ZipTip® was then 
washed with 10 |iL washing solution (0.1% TFA) by aspirating and dispensing into 
waste for 5 times. Finally the peptides were eluted with 2 |LIL elution solution (50% 
ACN/ 0.1% TFA) in a clean 0.5 mL tube by aspirated and dispensed 5 times. 
Only 0.5 )aL desalted sample was required to dot on the MS/MS plate and 
covered by matrix before loading to MS/MS machine. The MS/MS results were 
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searched by human database to identify the protein sample. 
2.3.1.2.4 Immunization of rabbits 
Transformed BL21 bacteria cell was pelleted by centrifuging the growth 
medium. IX SDS sampling buffer was used to resuspend the pellet. The total 
bacteria lysate was boiled in 99�C for 10 min before resolving in SDS-PAGE. After 
coomassie blue staining, the target band was cut and grind in a motor and pistol with 
protein extraction buffer. The purified rhIDUA protein was mixed with Freund's 
complete adjuvant (Sigma) for the first injection. In the following three injections, 
Freund's incomplete adjuvant (Sigma) was used. A total of four injections each use 
200 )ig, 200 jag, 100 \ig and 100 |ig rhIDUA protein respectively were performed in 
a biweekly basis in the Animal House of the Chinese University of Hong Kong. 
Table 2.4 summarized the details of antibodies produced by hIDUA synthetic 
peptides and E. co/z-derived rhIDUA protein. 
31 
Table 2.4 Details of IDUA antibodies produced by using either hIDUA synthetic 
peptides or E, o?//脑derived rhIDUA protein as antigens. 
Nature of antigen Name of rabbit Name of IDUA antibody 
hIDUA synthetic peptides 1 lA 1A 
IB IB 
hIDUA synthetic peptides 2 2A 2A 
2B 2B 
hIDUA synthetic peptides 3 3A 3A 
3B 3B 
E. co//-derived rhIDUA protein Bla Bla 
(N-IDUA) Bib Bib 
E. co//-derived rhIDUA protein B2a B2a 
(C-IDUA) ^ B ^  
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2.3.2 Affinity-purified antibodies 
Three affinity columns were constructed using cyanogen bromide-activated 
sepharose (CNBr) matrix (C9142, Sigma) coupled with synthetic hIDUA peptide 1, 
2 or 3 according to manufacturer's instructions. 
Rabbit serum (5 to 10 mL) was first spin by 1000 rpm for 5 min to collect the 
supernatant and dilute with IX PBS in 1:1 ratio, followed by mixing with the 
corresponding peptide-CNBr matrix in end-over-end mixer overnight at 4�C. The 
matrix was washed with IX PBS several times before the IDUA antibody was eluted 
with 0.2M glycine-HCl, pH 2.0 and collect the fractions in a 1.5 mL centrifuge tube 
containing IM Tris-HCl pH 8. The concentration of the purified antibody was 
measured with OD280 and then stored at -20°C. 
Similarly, protein A column was used to affinity-purified antibodies from rabbit 
serum immunized with E. co/z-dervied rhIDUA protein. 
2.3.3 Characterization of affinity-purified IDUA antibodies 
Western blot analysis was carried out to test the specificity of affinity-purified 
IDUA antibodies towards IDUA protein and their cross-reactivity towards BY-2 cell 
proteins. In addition, three recombinant IDUA proteins were used as positive 
controls for IDUA antibodies: CHO-full length IDUA, and E. coz7-dervied N-IDUA 
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and C-IDUA (in total bacterial protein or gel purified form). An IDUA antibody (US) 
provided by Dr. Todd C. Zankel (BioMarine Pharmaceutical, Inc. USA) was also 
used as a positive control. 
2.3.4 Construction of chimeric gene constructs 
In this study, the chimeric rhIDUA constructs in pBI221 vector were obtained 
from Tai Chi Seto (CUHK, Hong Kong). In SPi-IDUA-FLAG-526 and SPi-IDUA 
constructs, some extra mutations were reported by Tai Chi Seto (Table 2.5) The 
nucleotide sequences fidelity of the constructs was confirmed by DNA sequencing. 
The constructs were subcloned into pBI121 binary vector and transferred into 
tobacco BY-2 cells via Agrobacterium-mQ6i2iiQ(\ transformation as shown in Figure 
2.4a-d. 
Table 2.5 Extra mutations in the hIDUA chimeric gene constructs in this study. 
Construct name Position of oligonucleotide Codon change 
SPi-IDUA-FLAG-526 bp200 G to A (AGC to AAC) Codon 67: Ser to Asn (S67N) 
SPi-IDUA bp 1252 G to A (GTG to ATG) Codon 418: Val to Met (V418M) 
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Figure 2.4a Construction of SPp-IDUA 
The DNA fragment between the CaMV35S promoter and NOS terminator in pBI221 
was subcloned into pBI121 via BamHl/Sacl restriction sites to give the 
kanamycin-resistance construct SPp-IDUA. 35S, cauliflower mosaic virus 35S 
promoter; SPp, proaleurain signal peptide; IDUA, Human a-iduronidase cDNA 
without SP; Nos, nopaline synthase terminator; RB, right border; Nos Pro., Nos 
promoter; NPTII, neomycin phosphotransferase cDNA; Nos Ter., Nos terminator; 
GUS, p-D-glucuronidase cDNA and LB, left border. 
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Figure 2.4b Construction of SPi-IDUA 
The DNA fragment between the CaMV35S promoter and NOS terminator in pBI221 
was subcloned into pBI121 via BamHl/Sacl restriction sites to give the 
kanamycin-resistance construct SPi-IDUA. 35S, cauliflower mosaic virus 35S 
promoter; SPi, Human IDUA signal peptide; IDUA, Human a-iduronidase cDNA 
without SP; Nos, nopaline synthase terminator; RB, right border; Nos Pro., Nos 
promoter; NPTII, neomycin phosphotransferase cDNA; Nos Ter., Nos terminator; 
GUS, p-D-glucuronidase cDNA and LB, left border. 
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Figure 2.4c Construction of SPp-IDUA-T7-526 
The DNA fragment between the CaMV35S promoter and NOS terminator in pBI221 
was subcloned into pBI121 via BamHUSacl restriction sites to give the 
kanamycin-resistance construct SPp-IDUA-T7-526. 35S, cauliflower mosaic virus 
35S promoter; SPp, proaleurain signal peptide; IDUA, Human a-iduronidase cDNA 
without signal peptide; T7, T7 tag; S, SPACER which is a short Ser/Thr-rich 
sequence; BP-80 TMD, transmembrane domain of 80kDa binding protein;; a-TIP 
CT, cytoplasmic tail of a-tonoplast intrinsic protein; Nos, nopaline synthase 
terminator; RB, right border; Nos Pro., Nos promoter; NPTII, neomycin 
phosphotransferase cDNA; Nos Ten, Nos terminator; GUS, P-D-glucuronidase 
cDNA and LB, left border. 
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Figure 2.4d Construction of SPi-IDUA-FLAG-526 
The DNA fragment between the CaMV35S promoter and NOS terminator in pBI221 
was subcloned into pBI121 by BamHl/Sacl restriction sites to give the 
kanamycin-resistance construct SPi-IDUA-FLAG-526. 35S, cauliflower mosaic 
virus 35S promoter; SPi, Human IDUA signal peptide; IDUA, Human a-iduronidase 
cDNA without SP; FLAG, FLAG tag; S, SPACER which is a short Ser/Thr-rich 
sequence; BP-80 TMD, transmembrane domain of 80kDa binding protein; CT a-TIP, 
cytoplasmic tail of a-tonoplast intrinsic protein; Nos, nopaline synthase terminator; 
RB, right border; Nos Pro., Nos promoter; NPTII, neomycin phosphotransferase 
cDNA; Nos Ter., Nos terminator; GUS, P-D-glucuronidase cDNA and LB, left 
border. 
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2.3.5 Expression of IDUA in tobacco BY-2 cells 
2.3.5.1 Electropoartion of Agrohacteria 
The Agrohacteria competent cells were first thaw on ice and mix with 1 j^ L 
pi asm id DNA and incubate on ice for 1 min. They were then transfer to a pre-chilled 
0.2 cm electroporation cuvette and electroporate using GENE PULSER machine at 
25 |iF, 2.5 kV, 600 ohms. After pulse, 1 mL LB was added into cuvette and 
resuspend the mixture. The cell suspension was then transfer to tube and shake at 28 
�C for 2 hrs. After 2 hrs, the cell was spread on LB plates with 100 )ig/|LiL 
streptomycin and 50 fig/^L kanamycin and incubated at 28�C for 2 to 3 days until 
colony form. 
2.3.5.2 Agrobacterium-mediated transformation 
Agrobacteriiwi-mediated transformation was used to transform BY-2 cell. 
About 4 to 6 mL day-3 BY-2 suspension cell was transferred to Petri dish. And then 
use a 1 mL pipette to pipette up and down about 20 times to induce small lesions in 
the BY-2 cells and increase the efficiency of the transformation. After that 100 ).iL of 
transformed Agrobacterium was added into the Petri dish and mixed with the BY-2 
cell. A control was included by adding 100 ddHsO instead of Agrobacterium. 
The Petri dishes were wrapped with parafilm and incubate in dark at 28"C for 3 
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days. 
The mixture was then transfer to a 50mL Falcon and washed away the 
Agrobacterium by BY-2 culture medium, before plating on MS agar plates with 50 
}ig/mL kanamycin and 250 fig/mL cefotaxime. The plates were wrapped with 
parafilm and incubate at 28°C for 4 to 5 weeks until callus form, 
2.3.5.3 Screening of positive transformants 
The tiny tobacco BY-2 calli formed on the agar plates were transferred to a new 
agar plate with kanamycin (50 |ig/mL). Because the transgenic BY-2 calli contain 
kanamycin-resistance gene, this serve as the first selection of individuals containing 
the trans gene. 
2.3.6 Characterization of transgenic BY-2 cell expressing IDUA fusion 
2.3.6.1 Genomic DNA polymerase chain reaction (Genomic DNA PGR) 
2.3.6.1.1 Genomic DNA extraction from BY-2 callus 
BY-2 callus was transfer to a 1.5 mL eppendorf and then freeze in liquid 
nitrogen. Some glass beads were added into the eppendorf and a glass rod was used 
to grind the callus into powder. Five hundred microliter of CTAB (2% (w/v) CTAB, 
1.4M NaCl，20mM Na2EDTA, lOOmM Tris-HCl, pH 8.0) with 0.2% (v/v) 
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2-mercaptoethanol was added into the eppendorf and then incubated the eppendorf 
at 60°C for 40 mins with periodic mixing. Five hundred microliter of 24:1 CHCI3： 
isoamyl alcohol was then added and mix gently for 5 minute. The mixture was 
centrifuged at 14,000 rpm for 10 mins at 4�C. The supernatant was collected and 
two-third volume of isopropanol was added and gently mixed. The mixture was 
placed in -20�C for 30 min. Precipitate was collected by centrifugation of the 
mixture at 14,000 rpm for 15 mins at 4°C. The pellet was then washed by 500 |iL 
70% ethanol and the suspension was centrifuged again at 14,000 rpm for 10 mins at 
4�C and the pellet was air-dried. The dried pellet was dissolved in 50 jiL ddHaO. 
RNA removal was carried out by adding 5 )iL RNase (l}ig/mL) and incubated at 37 
°C for 1 hr and then stored at -20°C. The amount and quality of the extracted 
genomic DNA were checked by spectrophotometric measurement at OD260. 
2.3.6.1.2 Genomic DNA PGR of tobacco BY-2 callus 
Genomic DNA PGR was carried out to check the integration of chimeric gene 
constructs into BY-2 genome. The 15 \xL PGR mixture included 1 |iL genomic DNA, 
1.5 |iL 2mM dNTPs, L5|iL lOx PGR buffer, 1.5 |iL 25uM MgCls, 0.3 [iL 1-F primer, 
0.3 [iL 1-R primer and 0.3 |iL Tag DNA polymerase (1 unit/|iL). The PCR condition 
was as follow: 95 °C for 5 mins, 30 cycles of 95°C for 30 sec, 65。C for 30 sec and 
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72�C for 1.5 mins, followed by 1 cycle of 72�C for 10 mins. The PCR product was 
then separated by 1% agarose gel. 
2.3.6.2 Reverse transcription-PCR (RT-PCR) 
2.3.6.2.1 Total RNA extraction from BY-2 cell 
Total RNA of transgenic BY-2 cell was extracted using RNeasy® Plant Mini Kit 
(Qiagen, Avenue Stanford Valencia, CA) according to manufacturer's instructions. 
Total RNA was quantified by spectrophotometric measurement and then stored in 
-80°C until use. 
2.3.6.2.2 RT-PCR of BY-2 cell 
RT-PCR was carried out to check the presence of chimeric gene transcript 
(mRNA) in transgenic BY-2 cell. To remove DNA contamination, a 10 |iL DNase 
digestion mix containing 2.5 )ig total RNA, 1 |iL RQl RNase-free DNase I (1 
unit/jiL), 1 ^L RQl DNase-free lOx Reaction Buffer and DEPC-H2O was placed at 
RT for 15 mins and then terminate the reaction by the addition of 1 ]iL RQl DNase 
Stop Solution. The reaction mix was then incubated at 65 °C for 10 mins to 
inactivate the DNase. The treated RNA was mixed with 0.5 \ig IDUA specific 
primer 1-R and incubated at 70°C for 5 mins to melt the secondary structure within 
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the template. After that, 1 ]xL lOmM dNTPs, 1 fiL rRNAsin® ribonuclease inhibitor 
(40 units/jiL), 4 i^L Molony murine leukemia virus (M-MLV) 5X reaction buffer, 1 
|LIL M - M L V reverse transcriptase and 3 fiL DEPC-H2O were added to the reaction 
mix and incubated at 42°C for 1 hour. Another set of reaction without M-MLV 
reverse transcriptase was used as an internal negative control. After the first strand 
cDNA synthesis, a 50 fiL reaction mix PGR of cDNA was perform with 5 [iL RT 
product, 5 |iL 2mM dNTPs, 1 |iL 25mM MgCl�，5 )iL lOX PGR buffer, 1 jiL 1-F 
primer, 1 jiL 1-R primer and 0.3 ]iL Tag polymerase (1 unit/j^L). The PGR 
conditions was as follow: 95�C for 5 mins, 35 cycles of 95。C for 30 sec, 65�C for 
30 sec, 72°C for 1.5 mins, and 1 cycle of 72°C for 10 mins. The PGR product was 
separated by 1% agarose gel. 
2.3.6.3 Western blot analysis of BY-2 cell and medium 
2.3.6.3.1 Protein extraction from tobacco BY-2 cells and culture medium 
Fifty milliliter of seven-day-old tobacco BY-2 culture medium was centrifuged 
in 5,000 rpm for 10 mins to separate into cell and medium fraction. The medium 
fraction was collected and lyophilized in a freeze dry system. The dried pellet was 
resuspended in minimum amount of water and stored at -20�C. 
The cell fraction was frozen in liquid nitrogen and grinded by mortar and pestle 
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with 500 |LIL of 5X protein extraction buffer (5mM EDTA, 25mg/L leupeptin, 
750mM NaCl, O.SmM PMSF and 250mM Tris-HCl, pH 7.4). The homogenate was 
centrifuged at 14,000 rpm for 15 mins at 4�C. The supernatant was transferred to a 
new eppendorf as cell soluble fraction (CS fraction). Two hundred microliter IX 
protein extraction buffer was added to resuspend the pellet for the cell membrane 
fraction (CM fraction). A final concentration of 1% SDS was added to both CS and 
CM fractions and then boiled at 100。C for 10 mins. After cooling to RT, the CS 
fraction was directly stored at -20�C. The CM fraction was centrifuged at 14,000 
rpm for 15 mins at 4°C and the collected supernatant was stored at -20°C. 
2.3.6.3.2 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein samples were mixed with 5X sample loading buffer (1% 
2-mercaptoethanol, 0.01% bromophenol blue, 10% glycerol, 5% SDS and 62.5mM 
Tris-HCl, pH 6.8) and boiled at 100�C for 5 mins before resolving in 10% 
SDS-PAGE gel at 50V for 30 mins and llOV for 2 hrs. 
2.3.6.3.3 Immuno-detection and Coomassie blue stain 
After SDS-PAGE, the gel was either transferred to nitrocellulose membrane for 
immuno-detection or stained in Coomassie blue solution (1 g/L Coomassie brilliant 
blue G-250 and 1% methanol) and destained in destaining solution (ethanol: 100% 
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glacial acetic acid: water, 20:6:55). 
The gel was transferred to the nitrocellulose membrane by the modified Dunn 
carbonate transfer buffer (lOmM NaHCOs and 3mM NazHCCb) at 55V for Ihr and 
15mins using Mini Trans-Blot cell (Bio-Rad). The membrane was then rinsed with 
IX phosphate buffered saline (PBS) (68mM NaCl, 58mM NazHPO; and 17mM 
Na2P04-2H20) and incubated with shaking in blocking buffer (IX PBS, 5% 
skimmed milk powder) for 1 hr at RT. After washing with IX PBST (IX PBS and 
0.05% Tween-20), the membrane was then incubated with primary antibody at a 
concentration of 4 |ig/mL at 4�C overnight. Unbound primary antibody was 
removed by washing with IX PBST 3 times at 5 mins intervals. The membrane was 
incubated with shacking in anti-rabbit or anti-mouse secondary antibody at 1:8,000 
dilutions for 1 hr at RT. After washing away the unbound secondary antibody with 
IX PBST, the membrane was subjected to non-radioactive detection as described in 
the manual of Enhanced Chemiluminescence Kit (ECL, Amersham Pharmacia 
Biotech, Inc.). 
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2.3.7 Purification of IDUA from culture media 
Ammonium sulphate precipitation was used in the first step to purify IDUA in 
culture media. Ammonium sulphate was added to the culture medium at 10% 
incensement to determine the ammonium sulphate solubility of IDUA. The medium 
was stirred to dissolve the salt and left on ice for 20 mins, followed by centrifugation 
at 10,000 X g for 10 mins at 4°C. The supernatant was colleted and ammonium 
sulphate was further added to increase the saturation, while the pellet was dissolved 
with minimum volume of salt-free buffer. The procedures were repeated until no 
more ammonium sulphate dissolved. The proteins from pellet were separated by 





3.1 Generation of IDUA antibodies 
3.1.1 Cloning and expression of rhIDUA in E. coli 
N-IDUA and C-IDUA DNA was cloned and ligated to pGEM-T vector in E. 
coli strain DH5a (Figure 3.1 A). After DNA sequencing, N-IDUA and C-IDUA were 
transferred to pGEX-4T-1 vector in E. coli strain BL21 and checked by digestion 
(Figure 3.IB and C). E. coli was then induced to express either N-IDUA or C-IDUA 
As shown in Figure 3.2, a band at 60 kDa was observed in stained gel of induced E. 
coli samples (Figure 3.2A), which can be recognized by IDUA antibody in western 
blot analysis (Figure 3.2B). Thus, recombinant rhIDUA was successfully produced 
in E. coli. 
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Figure 3.1 Double digestion checking of IDUA insert in pGEM-T vector with 
BamHl and Xhol. 
(A) pGEM-T vector shown correct size of pGEM-T vector and insert. (B) and (C) 
pGEX-4T-l shown correct size of pGEX-4T-l vector and insert. U, uncut pGEM-T 
vector with IDUA insert. The alphabetic number indicates individual clones. 
Asterisk indicates the size of IDUA insert. 
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Figure 3.2 Induction of E. coli BL21 to produce N-IDUA and C-IDUA. 
The total bacterial protein was resolved in 10% SDS-PAGE and either (A) stained 
with Comassie blue or (B) transfer to nitrocellulose membrane for western blot 
analysis with IDUA antibody (provided by Dr. Todd C. Zankel, BioMarin 
Pharmaceutical Inc. USA). In the gel stain, an intense band of about 60 kDa was 
appeared in induced bacteria protein only and this band can be recognized by the 
antibody. U, uninduced; I, induced; M, molecular mass markers. Asterisk indicates 
the position of IDUA protein.    
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3.1.2 Characterization of IDUA antibodies 
3.1.2.1 Specificity of IDUA antibodies towards hIDUA protein 
Figure 2.2 shows the E. cc>//-derived rhIDUA and the hIDUA synthetic peptides 
used in this study to inject rabbits for the production of IDUA antibodies, while 
Table 3.1 shows the nature of antigens used in this study to raise IDUA antibodies 
and the expected recognized region of hIDUAby these antibodies. IDUA antibodies 
were further affinity-purified and used in subsequent analysis. 
The specificity and cross-reactivity of these affmity-purified IDUA antibodies 
were first tested via Western blot analysis using either E. co/Z-derived recombinant 
truncated IDUA or CHO-derived full-length rhIDUA as antigens. To do so，different 
forms of recombinant IDUA protein including E. co/z-derived N-IDUA and C-IDUA 
(in form of total protein and gel purified), and the Chinese Hamster Ovary (CHO) 
cell-derived rhIDUA were separated by SDS-PAGE, followed by western blot 
analysis using newly purified IDUA antibodies. As shown in Figure 3.3, both lA and 
IB antibodies specifically detected E. co/z-derived rhIDUA and CHO-derived 
rhIDUA (Figure 3.3A). Similarly, 2B but not 2A antibody specifically detected E. 
co/z-derived rhIDUA and CHO-derived rhIDUA (Figure 3.3B). In addition, the other 
antibodies (3A, 3B, Bla, Bib, B2a, and B2b) failed to detect either E. co/z-derived 
rhIDUA or CHO-derived rhIDUA (Figure 3.3C to D). As a positive control, the gift 
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IDUA antibodies from USA specifically detected E. co//-derived rhIDUA and 
CHO-derived rhIDUA (Figure 3.3F). Therefore, lA, IB and 2B antibody showed the 
best specificity for detecting either E. co//-derived N-IDUA and C-IDUA (in form of 
total protein and gel purified form) or CHO-derived full length rhIDUA. Table 3.1 
shows the summarized results from these Western blot analysis. 
After summarizing the results, IDUA antibody 1 A, IB and 2B can specifically 
recognize the expected region of hIDUA and their cross-reactivity with wild type 
tobacco BY-2 cell was further tested. 
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Figure 3.3 Characterization of newly generated, affinity-purified IDUA 
antibodies. 
Different forms of recombinant IDUA protein including E. co//-derived N-IDUA and 
C-IDUA (in form of total protein and gel purified), and the Chinese Hamster Ovary 
(CHO) cell-derived rhIDUA were separated by SDS-PAGE, followed by western 
blot analysis using new IDUA antibodies as indicated. Single and double asterisk 
indicate the position of E. co/z-derived rhIDUA protein and CHO-derived rhIDUA 
protein. M，molecular mass markers. 
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Table 3.1 The nature of antigens used to generate IDUA antibodies and their 
detection. 
IDUA Raised from antigens based Expected recognize region of hIDUA 
antibody on which part of hIDUA (real recognized region) 
Full length N-IDUA C-IDUA 
lA N-IDUA Yes (Yes) Yes (Yes) No (No) 
IB N-IDUA Yes (Yes) Yes (Yes) No (No) 
2A C-IDUA Yes (No) No (Yes) Yes (Yes) 
2B C-IDUA Yes (Yes) No (No) Yes (Yes) 
3A C-IDUA Yes (No) No (No) Yes (No) 
3B C-IDUA Yes (No) No (No) Yes (No) 
Bla N-IDUA Yes (No) Yes (Yes) No (Yes) 
Bib N-IDUA Yes (No) Yes (Yes) No (Yes) 
B2a C-IDUA Yes (No) No (Yes) Yes (Yes) 
B2b C-IDUA Yes (No) No (Yes) Yes (Yes) 
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3.1.2.2 Cross-reactivity of IDUA antibodies with wild type tobacco BY-2 cell 
To further study the cross-reactivity of these three antibodies toward tobacco 
BY-2 cell proteins, western blot analysis was further carried out. Cell soluble (CS) 
and cell membrane (CM) proteins were isolated from wild type BY-2 cells, followed 
by SDS-PAGE and western blot detection with these three antibodies 1 A, IB and 2B. 
As shown in Figure 3.4，lA antibody detected 3 bands (37 kDa, 70 kDa and 100 
kDa), IB antibody detected 1 band (70 kDa), while 2B antibody showed little 
cross-reactivity with wild type tobacco BY-2 cell protein. Since IB antibody had a 
higher affinity/titer than 2B antibody while 2B antibody shown no cross-reactivity 
with BY-2 cell proteins, both IB and 2B antibodies were used to detect IDUA in 
transgenic BY-2 cells in subsequent studies described below. Table 3.2 summarized 
results on the specificity and cross-reactivity of various newly generated IDUA 
antibodies toward recombinant IDUA proteins and endogenous tobacco BY-2 cell 
proteins. 
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Figure 3.4 Western blot analysis of cross-reactivity of IDUA antibodies with 
proteins of wild type tobacco BY-2 cells. 
Cell soluble (CS) and cell membrane (CM) proteins were isolated from wild type 
BY-2 cells, followed by SDS-PAGE and western blot detection with indicated 
antibodies. lA antibody detected 3 bands (37 kDa, 70 kDa and 100 kDa), IB 
antibody detected 1 band (70 kDa), while 2B antibody showed little cross-reactivity 
with wild type tobacco BY-2 cell protein. 
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Table 3.2 Summarized results of specificity and cross-reactivity of IDUA 
antibodies. 
Specificity Specificity towards E. co/z-derived Cross-reactivity 
IDUA towards full rhIDUA towards wild type 
antibody length IDUA tobacco BY-2 cell 
proteins 
Total bacterial Gel purified 
protein bacterial protein 
lA Good Good Good High 
IB Good Good Good Low 
2A Bad Bad Good High* 
2B Good Good Good No 
3A Bad Bad Bad No* 
3B Bad Bad Bad Low* 
Bla Bad Bad Good No* 
Bib Bad Bad Bad High* 
B2a Bad Bad Good High* 
B2b ^ ^ ^ Low*  
* Results not shown 
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3.2 Chimeric gene constructs construction and confirmation 
In this study, four chimeric rhIDUA constructs in pBI221 vector were obtained 
from Tai Chi Seto (CUHK, Hong Kong). All the constructs were checked by 
restriction digestion (Figure 3.5) and DNA sequencing. The results matched with 
hIDUA cDNA sequence from Prof. L.A. Clarke and the mutations reported by Tai 
Chi Seto (Table 2.1 and 2.5 in page 20 and 35). The constructs were subcloned into 
pBI121 binary vector (Figure 3.6 and 3.7) and transferred to Agrobacteria by 
electroporation (Figure 3.8 and 3.9). The Agrobacteria were then used to transform 
tobacco BY-2 cells. 
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1 2 3 4 
bp 1kb+ U B/S H/E U B/S H/S bp 1kb+ U B/S H/E IT^'b/S H/S 






U, uncut plasmid; B/S, BamHl and Sad double digestion gave about 2000 and 3500 
bp bands; H/E, HindUl and Sad double digestion gave about two 2800 bp bands; 
H/S, HindUl and Sad double digestion gave about two 2800 bp bands. The extra 
band (about 5600 bp) in 1 H/E and 2 H/S was due to incomplete digestion of 
plasmid. 
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( A ) SPP-IDUA-T7-526 ( B ) SPp-IDUA 
bp 1l<b+ -ve +ve 1 2 bp -ve +ve 1kb+"l ~ 
_ :::曙 111： ； 冬 • 
2 0 0 0 ^ ^ ^ iJ^fe 2 0 0 0 - ^ ^ z “ ^ ^ ^ ^ ^ ^ 
1650- mmrn mp; m p H P * 1650- Hw 雜辦 H^m ^ ^ * -WW 1000- 1000-
( C ) SPi-IDUA-FLAG-526 ( D ) SPi-IDUA 
bp 1kb+ -ve +ve 1 2 3 4 -ve -fve 1 2 3 5 1kb+ bp 
翻二 禱 禱 曙 m m m 
. . . 相 麵 , 
^ mmm 
,,,；‘r,；‘‘： 
女 塵 ^ ^ ^ 縫 一‘-2000 
^ ^ ^ ^ ^ W W f W -1650 
-1000 
Figure 3.6 PCR screening of integration of chimeric gene constructs into 
pBI121 in E, coli DH5a using IDUA 1-F and IDUA 2-R primers. The PCR 





hIDUA plasmid as template was used as positive control (+ve), water as template 
(-ve) were used as negative controls. The alphabetic number indicates individual 
clones. Asterisk indicates position of the amplified hIDUA gene at 1962 bp. 
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1 2 3 4 6 1 k b + b p 
‘ - 3 0 0 0 
…饭-m^ - 2 0 0 0 
‘•• . 
,肩珍M夢 
Figure 3.7 Digestion checking of chimeric gene constructs in pBI121 with 
BamHl and Sac\, 
1 SPp-IDUA-T7-526 with a 2175 bp insert 
2 SPp-IDUA with a 1962 bp insert 
3 SPi-IDUA-FLAG-526 with a 2166 bp insert 
4 pBI121 vector with a 1800 bp GUS 
5 SPi-IDUA with a 1962 bp insert 
Digestion of pBI121 vector was used to confirm the ligated chimeric gene constructs 
were not GUS. 
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SPp-IDUA-T7-526 SPp-IDUA SPi-lDUA-FLAG-526 SPi-IDUA 
bp 1j<b+ -ve +ve ~ 2 “ 2 3 ~ T " "1 2 “ 3 4 1 2 3 T 
M藝画麵編 
1000- > 二厂，糧"，々 m ‘ ‘ % 
Figure 3.8 PCR screening of integration of chimeric gene constructs into 
Agrobacteria using IDUA 1-F and IDUA 2-R primers. 
The PCR products were separated by 1% agarose gel. IDUA plasmid as template 
was used as positive control (+ve)，water as template (-ve) were used as negative 
controls. The alphabetic number indicates individual clones. Asterisk indicates 
position of the amplified hIDUA gene at 1962 bp. 
62 
bp 1kb+ 1 2 3 4 
彻US:圓爾 
3 0 0 0 " - , mm 圓 
2 0 0 0 - 、、釋 .、,， ,套食 
1 6 5 Q瞧 M H i 閥 , 
嫩!M勢务 ‘ 
•...X 務 游 ； ? 炒 . XX J；：：：. 
Figure 3.9 Digestion checking of chimeric gene constructs in transformed 
Agrobacteria with BamHl and Sad, 
1 SPp-IDUA-T7-526 with a 2175 bp insert 
2 SPp-IDUA with a 1962 bp insert 
3 SPi-IDUA-FLAG-526 with a 2166 bp insert 
4 SPi-IDUA with a 1962 bp insert 
Asterisks indicate the position of hIDUA chimeric gene. 
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Figure 3.10 shows the four chimeric constructs used to in this study to generate 
transgenic tobacco BY-2 cells and their predicted subcellular localization in these 
plant cells. Secretion of expressed IDUA into the culture media would allow easy 
detection and purification of recombinant IDUA, and ensure their proper folding (for 
constructs A & B); while PSV targeting of IDUA would allow its stable 
accumulation inside PSV (for constructs C & D). At least twenty individual 
transgenic BY-2 cell lines were generated for each construct to be used in further 
analysis. 
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KM一 ^ . , Predicted subcellular Name Construct _ ‘. ‘. localization 
(A) SPp-IDUA CaMV 3SS ^ gPp NOS | Secreted 
(B) SP 卜 IDUA ！ S e c r e t e d 
(C) SPP-IDUA.T7-526 | CaMV 35S V ^ l f c i i i l I 打 一 ^ "cT I I PSV 
(D) SPi-lDUA-FLAG-526 | OMV3SS ^ $Pi | FLAG | NOS | PSV 
Key 
I CaMV 3 5 ^ Cauliflower mosaic virus 35S promoter 8 Spacer _ K 
SPjpj Signal peptide of proaieuram ^ ^ H 
80-kDa bmoing protem transmembrane dofram 
|SP< Signal peptide of n-lduoranaiase 
H H H H I I I I ^ ^ m H .i-idurondiase ^ ^ ^ /-tonopiast intrinsic protein cytoplasmic tail 
r ^ T7 epitope fag j NOS Nopal.ne synthase term.nator 
L^AO{ FLAG epitope tag 
Figure 3.10 Chimeric human a-iduronidase (hIDUA) constructs used in this 
study to generate transgenic BY-2 cells and their predicated localization. 
(A) Construct SPp-IDUA contains a signal peptide of proaleurain and IDUA. 
(B) Construct SPi-IDUA contains signal peptide of human IDUA and IDUA. 
(C) Construct SPp-IDUA-T7-526 contains a signal peptide of proaleurain, IDUA, T7 
epitope tag, the transmembrane domain (TMD) of BP-80 (BP-80 TMD), and the 
cytoplasmic tail (CT) of a-tonoplast intrinsic protein (a-TIP CT). 
(D) Construct SPi-IDUA-FLAG-526 contains signal peptide of human IDUA, IDUA, 
FLAG epitope tag, BP-80 TMD and a-TIP CT. 
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3.3 Screening of transformed tobacco BY-2 callus with 
kanamycin-resistance 
Tiny tobacco BY-2 calli formed in MS agar plates added with kanamycin and 
cefotaxime in 4 to 5 weeks after transformation. The tiny calli were transferred to 
new MS agar plates with kanamycin for first selection. The calli were then checked 
by genomic DNA PCR to identify the positive transformants. The positive 
transfomants were subcultured into liquid medium for further analysis (Figure 3.11). 
_喜_ 
Figure 3.11 Kanamycin resistant screening of transformed BY-2 callus. 
A: Tiny calli formed on MS plate after 4 to 5 weeks after transformation. 
B: The tiny calli were subcultured to a new kanamycin plate for further screening 
and growth. 
C: The calli were subcultured into liquid medium for later use. 
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3.4 Genomic DNA PCR screening of transformed tobacco BY-2 
callus 
Genomic DNA PCR was then carried out to screen for transgenic cell lines 
with integrated IDUA DNA in the tobacco genome. Genomic DNA was first isolated 
from WT and transgenic BY-2 cells and used as template for PCR amplification with 
primers IDUA 1-F and 1-R to amplify IDUA. As shown in Figure 3.12, the DNA 
fragment corresponding to the right size of hIDUA was able to be amplified from 
most of the tested transgenic BY-2 cell lines expressing these four constructs. 
(Figure 3.12 A to D), which was missed from WT cells. Thus, IDUA DNA was 
successfully integrated into the genome of transgenic BY-2 cells. The number of 
positive transformants was shown in table 3.3. 
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(A) SPp-IDUA  
-ve WT +ve 1kb+ 1 21 61 94 96 100 103 150 157 170 (Cell line) 
:漏 
: : _ : : : 纖 画 — 灣 . 養 _ * ^ ^ ― 927 bp 
SPp-IDUA 
-ve WT +ve 1kb+ 8 55 57 59 91 96 112 120 156 164 183 185 189 191 (Cell line) 
_ . ^ 華一- … * 927 bp 
.:,: 像 If 
SPp-IDUA  
-ve WT +ve 1kb+ " 5 6 " " “ 8 9 1 0 4 133 137 178 N 4 ” “ “ ~ (Cell line) mjnnm.— 
(B) SPi-IDUA 
-ve WT +ve 1kb+"l 8 10 1 2 ~ 2 6 11 16 17 22 23 33 37 N5 N6 N20N24 (Cell line) 
= § - - • . ‘ i 户 g , • 927 bp 
„ 、 " ' 'AJk, —ik 'amk.請" 
SPi-IDUA  
-ve WT +ve 1kb+ 13 Sjs j j g ^ M N O P R S T U V (Cell line) 
^ 927 bp 
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(C) SPP-IDUA-T7-526 
-ve WT +ve 1kb+ 1 2 3 4 5 35 42 41 44 45 46 47 57 (Cell line) 
- - ” 、 ； ： 醒 
(D) SPi-IDUA-FLAG-526  
-ve WT +ve 1 k b + " l ~ 2 5 " " “ “ 6 7 8 9 10 11 12 16 18 19 20 (Cell line) 
SPi-IDUA-FLAG-526  
-ve WT +ve 1kb+ 21 22 23 24 25 26 27 28 (Cell line) 
垂 曹 … _ . 雷 灣 〒 ： _ , : ” . " 
H P : : ； 響 '::�'赛-:r； ； 927 bp 
… 、 德 麵 _ 截 _ 繼 , 娜 
Figure 3.12 Genomic DNA PCR screening of genomic DNA from wild type 
and transgenic tobacco BY-2 cells. 
Genomic DNA was isolated from WT and transgenic BY-2 cells as indicated and 
used as template for PCR amplification with primers IDUA 1-F and 1-R, followed 
by separation of PCR products in 1% agarose gel. hIDUA plasmid was used as a 
positive control (+ve), WT genomic DNA and no template (-ve) were used as 
negative controls. lkb+，DNA ladder. Asterisk indicates the position of amplified 
hIDUA gene of 927 bp. (A) SPp-IDUA, (B) SPi-IDUA, (C) SPp-IDUA-T7-526, and 
(D) SPi-IDUA-FLAG-526.  
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3.5 RT-PCR screening of transformed BY-2 cells 
RT-PCR was further used to study the expression of transformed genes from 
positively identified cell lines via genomic PCR. Total RNA was first extracted from 
these transgenic BY-2 cell lines, followed by DNase I digestion to remove DNA 
contamination and synthesis of first strand cDNA for subsequent RT-PCR analysis. 
As shown in Figure 3.13, RT-PCR products with expected size (927 bp) were 
detected from most transgenic BY-2 cell lines, while this product was absent from 
wild type (WT) cells and all internal controls. 18S rRNA was used as an internal 
house-keeping gene. These results indicated that the hIDUA chimeric gene 
transcripts (mRNA) were present in most transformants. The number of positive 
transformants was shown in table 3.3. 
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(A) SPp-IDUA 
WT 57 59 89 96 100 103 104 150 170 191 (cell line) 
-ve 1 kb+ +ve -ve +ve -ve +ve -ve +ve -ve +ve -ve +ve -ve +ve -ve +ve -ve +ve -ve +ve -ve +ve -ve 
W § m A m ^ mm S m # # i S ^ ^ ^ 彻 ’ i s s r R N A 
(B) SPi-IDUA  
WT 1 8 10 12 23 (cell line) 
-ve 1 kb+ +ve -ve +ve -ve +ve -ve +ve -ve +ve -ve +ve -ve 
- ,？ •. '、';... ""：> < .'•�‘ , ‘ 
'lOafi^ ‘‘‘ ‘ ‘ 
'：敏i, 
墨 # * 一 927bp 
(C) SPP-IDUA-T7-526  
WT 2 4 45 57 (cell line) 
-ve 1 kb+ +ve -ve +ve -ve +ve -ve +ve -ve +ve -ve 
• m d _ * 927 bp 
， “ • 遍 ^ '感 18S rRNA 
(D) SPi-IDUA-FLAG-526  
WT 2 4 6 9 12 (cell line) 
-ve 1 kb+ +ve -ve +ve -ve +ve -ve +ve -ve +ve -ve +ve -ve 
ipiSllWS^w ‘ , .. •遷 i囊運謹纖襲:.:.::、 
：霸：：：：•：；；；; : _ : _ _ _ 纖 _ 娜 
. _ ：遍_:::;::.漏 
- 鋒 霄 售 _ • * 一 927bp 
‘iifc务娜篇Jin 力 二 : 嫩 ' " “ j i i i f c 》 " i 8 s trna 
Figure 3.13 RT-PCR analysis of transgenic tobacco BY-2 cells. 
Total RNA was isolated from WT and transgenic BY-2 cells as indicated and used as 
template for first strand cDNA synthesis and then PCR amplification with primers 
IDUA 1-F and 1-R, followed by separation of PCR products in 1% agarose gel. 
Negative controls include the WT genomic DNA, no template (-ve) and the internal 
controls of individual cell lines without M-MLV in the reverse transcription process. 
18s rRNA was used as house-keeping gene. lkb+，DNA ladder. Asterisk indicates 
the position of amplified hIDUA gene of 927 bp. (A) SPp-IDUA, (B) SPi-IDUA, (C) 
SPp-IDUA-T7-526, and (D) SPi-IDUA-FLAG-526. 
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3.6 Western blot analysis of transformed tobacco BY-2 cells and 
culture media 
To further detect the expressed IDUA in transgenic tobacco BY-2 cell lines and 
culture media, Western blot analysis was then carried out. 
3.6.1 Tobacco BY-2 cells 
To detect intracellular IDUA proteins, both cell soluble (CS) and cell 
membrane (CM) proteins were isolated from transgenic and WT BY-2 cells, 
followed by SDS-PAGE and western blot analysis using either IB or 2B antibodies. 
As shown in Figure 3.14, IB antibody detected the endogenous tobacco protein at 
70 kDa in both WT and transgenic BY-2 cells (Figure 3.14 A to D, double asterisks). 
However, IB antibody specifically detected a band with the expected size of 
full-length IDUA at 78 kDa in transgenic BY-2 cells expressing SPp-IDUA (Fig. 
3.14A, asterisk), while such band was missed from the other transgenic BY-2 cell 
lines expressing the other three constructs (Figure 3.14 B, C & D), with the 
exception of one cell line expressing SPp-IDUA-T7-526 (Figure 3.14C), in which a 
band at 75 kDa was detected in the CS fraction (Figure 3.14C). These results 
indicated that IDUA was successfully expressed in some transgenic BY-2 cell lines 
expressing SPp-IDUA (Figure 3.14A). 
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However, no band was detected if using anti-T7 tag antibody (Figure 3.15), 
which could be due to processing and separating ofhDUA from T7 tag. 
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(A) SPp-IDUA  
WT 89 104 150 157 91 96 1oT" (Cell line) 
KDa! CS CM M CS CM CS CM CS CM CS CM CS CM CS CS CM 
50- � — 
SPp-IDUA  
WT 57 59 100 112 156 (Cell line) 
KDa CS CM M CS CM CS CM CS CM CS CM CS CM 
75、議… … _ r " | p i | § _ r � . ’’丨丨 
50- • ” 
(B) SPi-IDUA  
WT 1 8 12 10 (Cell line) 
KDa M CS CM CS CM CS CM CS CM CS CM 
100-
75- ,说一_ ji_丨丨丨丨丨丨丨丨丨 
50 
(C) SPP-IDUA-T7-526  
WT 2 4 44 45 46 57 1 3 (Cell line) 
KDa CS CM CS CM CS CM M CS CM CS CM CS CM CS CM CS CM CS CM 
1 0 0 - ‘ J 
售 ’|_n i n III I腳 I 輩jmrn^^ •** 
(D) SPi-lDUA-FLAG-526 
WT 2 4 6 9 12 24 25 (Cell line) 
KDa CS CM M CS CM CS CM CS CM CS CM CS CM CS CM CS CM 
100- ‘ 广 ’ t * 
mmmmmm HW ~ 讚~‘ mmmm^mg^f -尋禱 ** 
50- — ' 
Figure 3.14 Western blot analysis of intracellular IDUA protein in transgenic 
tobacco BY-2 cells using IB antibody. 
Cell soluble (CS) and cell membrane (CM) proteins were isolated from wild type 
and transgenic BY-2 cells expressing SPp-IDUA (A), SPi-IDUA (B), 
SPp-IDUA-T7-526 (C) and SPi-IDUA-FLAG-526 (D), followed by SDS-PAGE and 
western blot analysis with IB antibody. Single and double asterisk indicate the 
position of IDUA protein and endogenous tobacco BY-2 protein. M，molecular mass 
marker.  
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(A) SPp-IDUA- (B) SPp-IDUA-
丁 7-526 T7-526 
WT 2 WT 2 17 
CS CM CS CM M KDa kDa CS CM M CS CM +ve 
/…_100 
* 、華___ -75 1QQ_ 
/ 0- * 
� 




^m * * * 
25-
anti-T7 tag antibody 
Figure3.15 Western blot analysis of intracellular IDUA protein in transgenic 
tobacco BY-2 cells expressing SPp-IDUA-T7-526. 
Cell soluble (CS) fraction and cell membrane (CM) proteins were isolated from wild 
type and transgenic BY-2 cells expressing SPi-IDUA-FLAG-526, followed by 
SDS-PAGE and western blot analysis with anti-T7 tag antibody. T7 +ve, T7 positive 
control of 31 kDa. Single, double and triple asterisk indicates the position of IDUA 
protein, endogenous tobacco BY-2 protein and T7 positive control. M, molecular 
mass marker. 
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3.6.2 Tobacco BY-2 cell culture media 
Since SPp-IDUA was predicted to be secreted into culture media in transgenic 
BY-2 cells (Figure 3.10), I next collected culture media from both wild type and 
transgenic BY-2 cells expressing the four constructs and lyophilized，followed by 
SDS-PAGE and western blot analysis with IB antibody. As shown in Figure 3.16, a 
band at 78 kDa with the expected size of full-length IDUA was detected in the 
culture media of most transgenic BY-2 cell lines expressing SPp-IDUA (Figure 
3.16A，asterisk), but such band was missed from both WT BY-2 cells and the other 
transgenic BY-2 cell lines (Figure 3.16 B to D). Similar results were obtained when 
2B antibody was used in the same western blot analysis (Figure 3.17). Therefore, 
IDUA was successfully expressed and secreted in culture media in transgenic BY-2 
cell line expressing SPp-IDUA. Nine out of fourteen selected transformants (64.3%) 
expressed IDUA and secreted into medium. Table 3.3 and 3.4 summarized all results 
derived from the genomic DNA PCR, RT PCR and western blot analysis of 
transgenic BY-2 cell lines in this study. 
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(A) SPp-IDUA 
WT M 96 1 103 170 57 59 100 104 112 150 156 157 91 89 (cell line) 
150- . 




kDa WT M 1 8 12 10 (cell line) 
200-
150- “ 
1 0 0 - ‘ / 
75- * 
50- :: 閉 I 國 
37-
(C) SPP-IDUA-T7-526  
kDa WT M 44""""45 46 57 2 ~ 4 1 3~ (cell line) 
200-i 
150-
1 0 0 - -
75- * 
50- tm lli:::丨 
•：簡； 
(D) SPi-IDUA-FLAG-526  
kDa WT M ~ 2 ~ 4 6 9 1 2 ~ 2 4 25 (cell line) 
150-
100-
75- , * 
1:1:::•謹謹III:)::  
50- : _ :: 11 iiiiF :::::::德_• 
37- 7 ' 
25-
Figure 3.16 Detection of secreted IDUA using IB antibody. 
Culture media of wild type and transgenic BY-2 cells expressing SPp-IDUA (A), 
SPi-IDUA (B), SPp-IDUA-T7-526 (C), and SPi-IDUA-FLAG-526 (D) were 
collected and lyophilized, followed by SDS-PAGE and western blot analysis with 
IB antibody. Asterisk indicates the position of IDUA protein. M, molecular mass 
marker. 
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(A) SPp-IDUA  
kDa WT M 57 59 100 104 112 150 156 157 89 91 96 1 103 170 (cell line) 
；难:,、•'' > w 
75-', . � _ 麵 - “ “ 钃 i i M — * 
ilifc j：：：.：:圍;::遷_::_隱 
50-、< _ 幹 * * 
35--? m … 
25-
(B) SPi-IDUA 
kDa^ WT M “ 8 1 2 10 (cell line) 
200- ijm 150- f m 100- . ‘ _ 
75- ^ f e * 
50- 會众 ^ m . 
37- , .；. 
(C) SPP-IDUA-T7-526  
kDa WT M " S 4 5 4 6 s T ~ 2 ~ 4 3 (cell line) 
m 
. ： ^M：. 一^^^^^ .:. ‘；. 聚 
(D) SPi-IDUA-FLAG-526  
kDa WT M 2 4 6 9 12 24 25 (cell line) 
150�' 
1 0 0 - ‘ ： 
75- ：：•纖： f ^ z f , * 
50- _ ' 麵 
37- "•"’ 
25-
Figure 3.17 Detection of secreted IDUA using 2B antibody. 
Culture media of wild type and transgenic BY-2 cells expressing SPp-IDUA (A), 
SPi-IDUA (B), SPp-IDUA-T7-526 (C), and SPi-IDUA-FLAG-526 (D) were 
collected and lyophilized, followed by SDS-PAGE and western blot analysis with 
2B antibody. Asterisk indicates the position of IDUA protein. M, molecular mass 
marker. 
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Table 3.3 Summarized results of genomic DNA PGR, RT-PCR and western blot 
analysis of transgenic tobacco BY-2 cells. 
Construct Total no. of callus Genomic Total Western blot +ve 
formed after DNA PGR RNA 
transformation +ve RT-PCR 
+ve 
Cell Medium 
SPp-IDUA 196 26/34 10/10 4/14 9/14 
(76.5%) (100%) (28.6%) (64.3%) 
SPi-IDUA 91 9/30 3/5 0/4 0/4 
(30%) (60%) (0%) (0%) 
SPp-IDUA-T7-526 57 11/13 4/4 1/8 0/8 
(84.6%) (100%) (12.5%) (0%) 
SPi-IDUA-FLAG-526 24 9/24 4/5 0/7 0/7 
(37.5%) (80%) (0%) (0%) 
% = Percentage of positive cell lines 
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Table 3.4 Details of transgenic tobacco BY-2 cell line showing positive results in 
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3.7 Puri f icat ion of I D U A protein in culture media 
Western analysis of ammonium sulphate precipitated protein from culture 
media showed that IDUA protein was precipitated at 60%-80% ammonium sulphate 
saturation (Figure 3.18). This can be used as a method to concentrate IDUA in 
culture media and later for the purification use. 
0% 10% 20% 40% 60% 80% M kDa 
-100 
^ -50 
Figure 3.18 Ammonium sulphate precipitation of IDUA in culture media. 
Proteins in the tobacco BY-2 culture media were precipitated by different percentage 
saturation of ammonium sulphate, followed by SDS-PAGE separation of protein and 





In this study, two out of three hIDUA synthetic peptides could raise specific 
IDUA antibodies. However, there were differences in the specificity towards IDUA 
protein and cross-reactivity with wild type tobacco BY-2 protein between the 
antibodies. This may due to the difference in the immune response of individual 
rabbit and made it difficult to ensure the quality of antibodies produced. Also, there 
is lack of protein sequence database for tobacco. So the sequences chosen for 
synthetic peptides may have homolog with tobacco proteins and led to the 
cross-reactivity. 
Theoretically, using rhIDUA proteins as antigen to raise IDUA antibody should 
give more specific antibody as rhIDUA proteins should contain more epitopes than a 
short synthetic peptide. However, in this study, using hIDUA synthetic peptides as 
antigen gave more specific antibodies than that of rhIDUA proteins. This might be 
due to the impurity of the gel purified rhIDUA proteins. Although the purified 
rhIDUA proteins were checked by SDS-PAGE and western blotting to ensure the 
purity of antigens，contaminated proteins with similar molecular weight might be 
present In addition, synthetic peptides were smaller and in liquid form which was 
easier to inject into rabbit and to be absorbed. The gel purified rhIDUA proteins 
were gel mixture and difficult to inject into rabbit and to be absorbed. Also, the 
immune response of individual rabbit was different and made it difficult to ensure 
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the quality of antibodies produced. 
For the expression of IDUA in tobacco BY-2 cell, transgenic tobacco BY-2 cell 
lines were successfully produced. The four chimeric hIDUA constructs were 
successfully transformed into tobacco BY-2 cells as confirmed by genomic DNA 
PGR and RT-PCR. However, only constructs using proaleurain signal peptide 
including SPp-IDUA-T7-526 and SPp-IDUA showed IDUA expression in western 
blot analysis. One the other hand, constructs using hIDUA signal peptide including 
SPi-IDUA-FLAG-526 and SPi-IDUA showed undetectable IDUA expression in 
western blot analysis. The following reasons might account for this observation: the 
non-plant signal peptide was not recognized by the plant protein system and the 
expression of IDUA was too low to be detected. The low level of expression could 
be due to the difference in codon usage between tobacco and human. 
In western analysis of intracellular protein using IB antibody, 
SPp-IDUA-T7-526 showed a 75kDa band in the cell soluble fraction, however no 
band was detected when using anti-T7 tag antibody. Since the expected size of 
IDUA fusion with BP-80 TMD and a-TIP CT is 79kDa, this result indicated that the 
detected IDUA at 75kDa was cleaved from the T7 epitope tag and BP-80 TMD and 
a-TIP CT. Such cleavage could occur in the vacuole of BY-2 cells and thus resulted 
in soluble IDUA in the CS fraction. The larger size of IDUA at 75 kDa compared to 
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the predicted 72 kDa full-length IDUA might be due to plant-derived glycosylation 
of the protein. 
Most transgenic BY-2 cell lines with detectable IDUA in western blot analysis 
were derived from cells expressing construct SPp-IDUA which target IDUA to the 
cell exterior and into the culture media via a default pathway. In fact, a 78kDa 
protein corresponding to glycosylated IDUA was detected by IDUA antibodies in 
both intracellular and culture media. The secreted IDUA might be more stable than 
those inside the cells because of the enzymatic systems inside the BY-2 cells, which 
might account for the un-success in detecting IDUA in cell lines expressing the two 
constructs targeted for PSV localization. Previous study on CHO-derived rhIDUA 
also found that only the secreted rhIDUA contained phosphorylated oligosaccharides 
while the intracellular one was dephosphorylated after reaching the lysosome (Zhao 
et al., 1997). However, transgenic BY-2 cells expressing the full-length human 
IDUA (construct B SPi-IDUA) failed to show detectable IDUA inside the cells or in 
culture media, which might be due to the possibility that the plant system does not 
recognize the signal peptide sequences from the human IDUA gene properly. 
Therefore, a plant signal peptide sequences, such as the prolaeurain signal peptide 
(Tse et al., 2004), are recommended to be used in making a fusion with other 
non-plant genes/proteins in future study. 
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The yield of secreted IDUA in culture media was estimated to be 17.5% of the 
total secreted protein, a significant increase over a previous study where 
0.002-0.003% IDUA of total soluble proteins was detected in transgenic tobacco 
seeds (Seto, 2004). However, the activity of secreted IDUA remains to be 
determinated. 
The secreted IDUA in cultured media of SPp-IDUA cells cannot be directly 
used in the enzyme replacement therapy because plant-derived IDUA does not have 
mannose-6-phosphate (M6P) tag which is important for M6P-receptor-mediated 
endocytosis for targeting to lysosomes in the enzyme replacement therapy. This 
problem can be solved by in vitro addition of M6P tag via hexokinase. Alternatively, 
a receptor system that does not depend on the glycosylation patterns of IDUA can 
also be used. Low density lipoprotein receptor (LDLR) family is one of the widely 
distributed receptor in our body. For example, LDLR-related protein 1 (LRPl) and 
megalin/LRP2, are endocytic receptors that transport LDL protein to lysosome. 
LDLR family is bound with high affinity with receptor associated protein (RAP), 
which is a chaperone and assists in proper folding of receptors. Thus, IDUA fusion 
with RAP had been found to be successfully uptake by lysosomal storage disease 
patient fibroblasts and the RAP was degraded by lysosomal enzyme and leaving 
IDUA intact (Prince et al., 2004). The usage of lipoprotein receptor system can also 
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increase the cellular delivery and IDUA can even cross the blood-brain barrier 
(Prince et a/.，2004). 
Plant specific complex N-link glycan present in the secreted IDUA is another 
problem. This can be solved by knockout the plant Golgi enzyme pl，2 
xylosyltransferase and a l , 3 fucosyltransferase to prevent complex glycan addition 
in plant Golgi (Koprivova et al., 2004). In addition, knock-in tobacco plants with 
human Golgi enzymes had successfully added pi,4 galactose residues to 
plantibodies to make humanized antibody (Bakker et al., 2001). Research using 
Arabidopsis cgl (complex glycan-deficient) seeds that mutated in N-acetyl 
glucosamine (GlcNAc) transferase I (the first enzyme in complex glycan synthesis 
pathway) in early Golgi had also successfully produced enzymatically active IDUA 
without plant-specific complex glycans (Downing et al., 2006) 
The BioMarine/Genzyme Pharmaceutical Inc. (Aldurazyme® producer) claimed 
that their product can satisfy 70% (2400 out of 3400 patients per year) of the market 
in the economically developed world. However, the real number of patients in the 
world especially in the developing countries is far underestimated. Therefore, using 
plant cells to produce cheaper IDUA has its potential market. 
In conclusions, I have successfully generated transgenic tobacco BY-2 cells 
expressing various IDUA fusions and demonstrated that secreted IDUA was detected 
87 
in cells expressing SPp-IDUA. Further studies include purification of plant-derived 
IDUA from the culture media for confirmation of IDUA identity via protein 
sequencing or MS/MS analysis and for enzymatic assay using a mouse system. In 
addition, the secretion of IDUA into the exterior space of transgenic BY-2 cells can 
also be further confirmed via confocal immunofluorescence and immunoEM studies 
with specific IDUA antibodies. This secretion system in BY-2 cells may represent an 
efficient way for the production and purification of pharmaceutical recombinant 
proteins in plant cell bioreactors. 
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Chapter 5 
Summary and Future Perspectives 
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5.1 Summary 
5.1.1 Specific IDUA antibodies were generated 
In this study, specific IDUA antibodies were successfully generated using 
hIDUA synthetic peptides as antigens to immunize rabbits. These antibodies had had 
little cross-reactivity with endogenous tobacco BY-2 proteins. 
5.1.2 Transgenic tobacco BY-2 cells were generated 
Transgenic tobacco BY-2 cell lines expressing various IDUA fusions were 
successfully generated. The four chimeric hIDUA constructs were successfully 
transformed into tobacco BY-2 cell as confirmed by genomic DNA PCR and 
RT-PCR. All the constructs were expressed at the transcriptional level. 
5.1.3 Constructs with plant signal peptide were expressed at translational level 
Transgenic BY-2 cells expressing constructs with proaleurain signal peptide 
(SPp-IDUA-T7-526 and SPp-IDUA) showed IDUA expression at the protein level. 
However, BY-2 cells expressing constructs with hIDUA signal peptide 
(SPi-IDUA-FLAG-526 and SPi-IDUA) showed no detection of IDUA protein. Such 
difference might be due to either the non-plant signal peptide was not recognized by 
the plant ER system，or the expression level of IDUA was too low to be detected. 
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Therefore, plant signal peptide should be used in future study of using plants as 
bioreactors to produce human lysosomal proteins. 
5.1.4 IDUA detected in the culture media 
SPp-IDUA which target IDUA to secretion contained no vacuolar sorting 
determinant and thus targeting for secretion. Therefore IDUA synthesized in ER 
would be transported to Golgi and then secrete out of the cell via the default 
pathway. The size of the secreted IDUA in the culture media was larger than the 
expected size of IDUA, which could be due to glycosylation of the IDUA in its 
pathway from ER to Golgi to cell exterior. 
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5.2 Future perspectives 
Confocal immuno florescence microscopy and immuno electron microscopy 
will be carried out to study the subcellular localization of IDUA in transgenic 
tobacco BY-2 cells. In the secreted cell lines, IDUA is expected to localize in the 
apoplast. 
Since the ultimate goal is to produce bioactive plant-derived IDUA for enzyme 
replacement therapy, IDUA will be purified from culture media to test its biological 
activity. The purification can be done by first concentrating the culture media via ^ 
ammonium sulphate precipitation, followed by affinity-purification of IDUA using 
IDUA antibody column, or using size exclusion gel purification. 
Uptake of IDUA into human blood is achieved by M6P-receptor-mediated 
endocytosis for targeting to lysosomes. In order to solve the problem of lacking M6P 
tag in plant-derived IDUA, an alternative receptor system that does not depend on 
the glycosylation pattern can be used. IDUA fusion with a low-density lipoprotein 
receptor family protein had been found to be successfully uptake by lysosomal 
storage disease patient fibroblasts (Prince et al., 2004). The usage of lipoprotein 
receptor system can increase the cellular delivery and IDUA can even cross the 
blood-brain barrier. Alternatively, M6P tag can be added chemically in vitro to 




Characterization of an Unknown 
Protein by IB Antibody 
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6.1 Introduction 
As previously shown in chapter 3，IB antibody specifically detected an 
endogenous protein of 70 kDa in wild type tobacco BY-2 cells. It would be 
interesting to find out the identity of this protein and study its subcellular 
localization using IB antibody, so that IB antibody can be used as an organelle 
marker for this protein. 
6.2 Objectives 
Specific objectives of this research are as follows: 
(1) To find out if IB antibody detects the same protein across different plant 
species. 
(2) To study the subcellular localization of that unknown protein. 
(3) To identify the unknown protein recognized by IB antibody. 
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6.3 Materials and Methods 
6.3.1 Western blot analysis of different plant species 
Proteins from different plant species including Arabidopsis, tobacco (mature 
seed and BY-2 cell), mung bean, and rice were extracted and detected by western 
blot with IB antibody as described in section 2.3.6.3. 
6.3.2 Subcellular localization of the unknown protein 
Sucrose gradient fractionation was performed to find out the localization of this 
endogenous protein in Arabidopsis suspension culture cells as previously described 
(Tse et al., 2004). The fractions were collected, followed by proteins extraction and 
separation by SDA-PAGE and western blot analysis using IB antibody. 
Confocal immunofluoresence was also performed as previously described 
(Jiang and Rogers, 1998) to further study the subcellular localization of this protein 
in tobacco BY-2 cells and mature tobacco seeds. 
6.3.3 Affinity-purification of the unknown protein 
Affinity column was constructed using cyanogens bromide-activated sepharose 
(CNBr) matrix (C9142, Sigma) coupled with IB antibody according to 
manufacturer's instructions. Cell soluble extract from Arabidopsis suspension 
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culture cells was mixed with the CNBr matrix. The procedures were the same as that 
described in section 2.3.2. The eluted fractions were separated by SDS-PAGE, 
followed by western blot analysis using IB antibody. A gel stain was also performed 
at the same time and the corresponding band to IB antibody detection was cut from 
the gel and used in LC-MS/MS analysis. The procedure of LC-MS/MS analysis was 
described in section 2.3.1.2.3 without desalting by ZipTip®. The sample was run 
through the LC machine before loading to MS/MS machine. 
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6.4 Results 
6.4.1 Western blot analysis of different plant species 
To find out if IB antibody also detect the same 70 kDa protein from different 
plant species, both CS and CM proteins were isolated from BY-2 cells, Arabidopsis 
cells, rice cells, tobacco seeds and mungbean roots, followed by SDS-PAGE and 
western blot analysis using IB antibody. 
As shown in Figure 6.1，a protein of 70 kDa was detected in all tested proteins 
including Arabidopsis, tobacco (mature seed and BY-2 cell), mung bean, and rice. 
Therefore, IB antibody detected the same protein in various plant species. From 
now on, the protein detected by IB antibody is termed IB protein. 
Mung Bean 
Tobacco seed BY-2 Arabidopsis root Rice 
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100 
7 5 _ _麵 
5 0 
3 7 
Figure 6.1 Cross-reactivity of IB antibody in different plant species. 
Cell soluble (CS) and cell membrane (CM) proteins were isolated from tobacco 
(mature seed and BY-2 cells), Arabidopsis cells, mung bean, and rice, followed by 
SDS-PAGE and western blot analysis with IB antibody. Asterisk indicates the 
position of endogenous protein detected by IB antibody. M，molecular mass marker 
in kDa. 
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6.4.2 Subcellular localization of an unknown protein 
To study the subcellular localization of IB protein, sucrose gradient 
fractionation was carried out. Protoplasts were first prepared from Arabidopsis 
culture cells, followed by breakage of plasma membrane and loading of cytosolic 
contents onto a sucrose gradient. After ultracentrifugation, fractions were collected, 
followed by protein extraction, SDS-PAGE and western blot analysis using IB 
antibody. As shown in Figure 6.2, the IB protein was mainly found in fractions 10 to 
16 that are corresponding to PVC factions (Tse et al., 2004). 
Confocal immunofluorescence was further carried out to study the subcellular 
localization of IB protein in tobacco BY-2 cells. As shown in Figure 6.3, IB 
antibody gave out punctate signals in tobacco BY-2 cells, which was separated from 
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Figure 6.2 Western blot analysis of Arabidopsis organelle proteins from 
sucrose gradient fractionation using IB antibody. 
Arabidopsis organelles were fractionated by sucrose gradient, followed by collection 
of various fractions for SDS-PAGE and western blot analysis using IB antibody. 
Asterisk indicated position of detected protein. M, molecular mass marker in kDa. 
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Figure 6.3 Confocal images of IB antibody in wild type (WT) tobacco BY-2 
cells. 
WT tobacco BY-2 cells were fixed and labeled by IB antibody. Panel A showed the 
fluorescent signals from BY-2 cells using Rhodamine-conjugated secondary 
antibody (panel 1 and 2). Panel B showed the florescent signals using 
FITC-conjugated secondary antibody (panel 3 and 4). In each panel, a control 
without IB antibody was included. Bar = 50 jum. 99 
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Figure 6.4 Confocal immunofluorescent studies of IB antibody in transgenic 
BY-2 cells expressing the Golgi marker GONSTl-YFP. 
GONSTl-YFP tobacco BY-2 cells were fixed and labeled wtih IB antibody. Panel A 
showed the fluorescent signals of GONSTl-YFP (green) and from IB antibody (red). 
Panel B showed a control without IB antibody. Bar = 50 |Lim. 
100 
To further find out the subcellular localization of IB protein in tobacco seeds, 
paraffin-sections were prepared from mature tobacco seeds and used in 
immuno-labeling with IB antibody. As shown in Figure 6.5, single labeling with IB 
antibody generated circular signals in endosperm cells, while punctate signals were 
detected in embryo cells. Double-labeling with PSV marker a-TIP antibody further 
demonstrated that IB protein located to PSV in tobacco seeds (Figure 6.6). 
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Figure 6.5 Confocal immunofluorescent studies of IB antibody in mature 
tobacco seeds. 
(A) Structure of a mature tobacco seed showing the endosperm and embryo. 
(B) The mature tobacco seeds were fixed and sectioned, followed by signal labeling 
with IB antibody. Panel A showed the fluorescent signals from mature seeds (Panel 
1: endosperm; panel 2: embryo) using Rhodamine-conjugated secondary antibody. 
Panel B showed the florescent signals (Panel 1: endosperm; panel 2: embryo) using 
FITC-conjugate secondary antibody. Bar = 50 |Lim. 
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Figure 6.6 Confocal immunofluoresent studies using IB and a-TIP 
antibodies in mature tobacco seeds. 
The mature tobacco seeds were fixed and sectioned, followed by double labeling 
with a-TIP primary antibody detected by FITC-conjugated secondary antibody 
(green), and IB primary antibody detected by Rhodamine-conjugated secondary 
antibody (red). When green and red images were superimposed, colocalization of 
two fluorescent signals was indicated by a yellow colour. Arrows indicate examples 
of IB protein inside PSV (Panel 1-3). Bar = 50 inm.  
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6.4.3 Affinity-purification of IB protein 
To further identify the identity of IB protein, affinity column with IB antibody 
was used to purify IB protein for further analysis. Proteins were extracted from 
Arabidopsis culture cells, followed by binding using the column and subsequently 
protein elution. Eluted proteins were then separated by SDS-PAGE, followed by 
western blot detection using IB antibody. As shown in Figure 6.7, a 70 kDa band 
was detected by IB antibody (Figure 6.7). The corresponding band of IB protein 
stained gel was cut for LC-MS/MS analysis for protein identification. 
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Figure 6.7 Affinity-purified IB protein. 
Single and double asterisks indicate position of IB protein and IgG eluted from the 
affinity column. 
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6.5 Summary and Future Perspectives 
6.5.1 Summary 
(1) IB antibody specifically detected a protein of 70 kDa in different plant species 
including Ambidopsis, tobacco (mature seed and BY-2 cell), mung bean, and 
rice. 
(2) Study of sucrose gradient fractionation indicated that IB protein was 
concentrated at the PVC fractions. 
(3) Confocal immunofluorescent study demonstrated the subcellular localization 
of the organelles labeled by IB antibody were separated from Golgi in BY-2 
cells; while IB protein was found to located inside PSV in mature tobacco 
seeds. 
6.5.2 Future Perspectives 
The identity of IB protein will be resolved by LC-MS/MS analysis. This study 
will allow us to use IB antibody as an additional marker for plant cell biologists, and 
study the biology of IB protein in future research. 
105 
References 
Bakker, H., Bardor, M.，Molthoff, J.W., Gomord, V., Elbers, I., Stevens, L.H., 
Jordi, W., Lommen, A., Faye, L., Lerouge, P., and Bosch, D. (2001). 
Galactose-extended glycans of antibodies produced by transgenic plants. 
Proc Natl Acad Sci U S A 98，2899-2904. 
Bednarek, S.Y., Wilkins, T.A., Dombrowski, J.E., and Raikhel, N.V. (1990). A 
carboxyl-terminal propeptide is necessary for proper sorting of barley lectin 
to vacuoles of tobacco. Plant Cell 2，1145-1155. 
Chrispeels, M.J., and Raikhel, N.V. (1992). Short peptide domains target proteins 
to plant vacuoles. Cell 68，613-616. 
Conrad, U., and Fiedler, U. (1998). Compartment-specific accumulation of 
recombinant immunoglobulins in plant cells: an essential tool for antibody 
production and immunomodulation of physiological functions and pathogen 
activity. Plant Molecular Biology 38，101-109. 
Denecke, J., Botterman, J•，and Deblaere, R. (1990). Protein secretion in plant 
cells can occur via a default pathway. Plant Cell 2，51-59. 
Dombrowski, J.E., Schroeder, M.R., Bednarek, S.Y., and Raikhel, N.V. (1993). 
Determination of the functional elements within the vacuolar targeting signal 
of barley lectin. Plant Cell 5，587-596. 
Doran, P.M. (2000). Foreign protein production in plant tissue cultures. Current 
Opinion in Biotechnology 11, 199-204. 
Dorfman, A., and Matalon, R. (1976). Proc. Nat. Acad. Sci. USA, 630-637. 
Downing, W.L., Galpin, J.D., Clemens, S.，Lauzon, S.M., Samuels, A.L., 
Pidkowich, M.S., Clarke, L.A., and Kermode, A.R. (2006). Synthesis of 
enzymatically active human a-L-iduronidase in Arabidopsis cgl (complex 
glycan-deficient) seeds. Plant Biotechnology Journal 4, 169-181. 
Drossard, J., Nahring, J.M., Hellwig, S., and Fischer, R. (1997). Production of 
engineered antibodies in tobacco plants and cell suspension cultures. IBC's 
8th annual international conference on antibody engineering, 69-93. 
During, K.，Hippe, S., Kreuzaler, F.，and Schell, J. (1990). Synthesis and 
self-assembly of a functional monoclonal antibody in transgenic Nicotiana 
tabacum. Plant Molecular Biology 15, 281-293. 
Fischer, R., Liao, Y.C., and Drossard, J. (1999a). Affinity-purification of a 
TMV-specific recombinant full-size antibody from a transgenic tobacco 
suspension culture. Journal of Immunological Methods 226, 1-10. 
Fischer, R.，Emans, N.，Schuster, R, Hellwig, S., and Drossard, J. (1999b). 
Towards molecular farming in the future: using plant-cell-suspension 
106 
cultures as bioreactors. Biotechnology and Applied Biochemistry 30 ( Pt 2), 
109-112. 
Fischer, R., Liao, Y.C., Hoffmann, K.，Schillberg, S., and Emans, N. (1999c). 
Molecular farming of recombinant antibodies in plants. Biological Chemistry 
380, 825-839. 
Fung, K丄•，Yim, Y.F., Tse, Y.C., Miao, Y.，Sun, S.S., and Jiang, L. (2005). 
Targeting and processing of membrane-anchored YFP fusion proteins to 
protein storage vacuoles in transgenic tobacco seeds. Seed Science Research 
15, 361-364. 
Hara-Nishimura, I.L, Shimada, T., Hatano, K., Takeuchi, Y., and Nishimura, M. 
(1998). Transport of storage proteins to protein storage vacuoles is mediated 
by large precursor-accumulating vesicles. Plant Cell 10，825-836. 
Hellwig, S., Drossard, J.，Twyman, R.M., and Fischer, R. (2004). Plant cell 
cultures for the production of recombinant proteins. Nature Biotechnology 
22, 1415-1422. 
Hers, H.GL (1965). Inborn Lysosomal Diseases. Gastroenterology 48, 625-633. 
Hiatt, A , Cafferkey, R., and Bowdish, K. (1989). Production of antibodies in 
transgenic plants. Nature 342, 76-78. 
Holwerda, B.C., Padgett, H.S., and Rogers, J.C. (1992). Proaleurain vacuolar 
targeting is mediated by short contiguous peptide interactions. Plant Cell 4, 
307-318. 
Hopwood, J.J., and Morris, C.P. (1990). The mucopolysaccharidoses. Diagnosis, 
molecular genetics and treatment. Molecular Biology and Medicine 7, 
381-404. 
Jiang, L., and Rogers, J.C. (1998). Integral membrane protein sorting to vacuoles 
in plant cells: evidence for two pathways. The Journal of Cell Biology 143, 
1183-1199. 
Jiang, L.，and Rogers, J.C. (1999). Functional analysis of a Golgi-localized 
Kex2p-like protease in tobacco suspension culture cells. The Plant Journal 18， 
23-32. 
Koprivova, A., Stemmer, C., Altmann, E, Hoffmann, A., Kopriva, S.，Gorr, G, 
Reski, R., and Decker, E.L. (2004). Targeted knockouts of Physcomitrella 
lacking plant-specific immunogenic N-glycans. Plant Biotechonology 
Journal 2, 517-524. 
Kwon, T.H., Seo, J.E., Kim, J., Lee, J.H., Jang, Y.S., and Yang, M.S. (2003). 
Expression and secretion of the heterodimeric protein interleukin-12 in plant 
cell suspension culture. Biotechnology and Bioengineering 81，870-875. 
Larrick, J.W., Yu, L.，Chen, J., Jaiswal, S., and Wycoff, K. (1998). Production of 
antibodies in transgenic plants. Research in Immunology 149，603-608. 
107 
Magnuson, N.S., Linzmaier, P.M., Reeves, R.，An, G, HayGlass, K., and Lee, 
J.M. (1998). Secretion of biologically active human interleukin-2 and 
interleukin-4 from genetically modified tobacco cells in suspension culture. 
Protein Expression and Purification 13, 45-52. 
Matsuoka, K.，and Nakamura, K. (1991). Propeptide of a precursor to a plant 
vacuolar protein required for vacuolar targeting. Proceedings of the National 
Academy of Sciences of the United States of America 88, 834-838. 
Neufeld, E.F., and Muenzer, J. (1995). The mucopolysaccharidoses. In The 
metablic and molecular bases of inherited disease, C.R. Scriver, A丄. 
Beaudet，W.S. Sly, and D. Valle, eds (New York McGraw-Hill, Health 
Professions Division), pp. 1565-1587. 
Neufeld, E.F., Lim, T.W., and Shapiro, L.J. (1975). Ann. Rev. Biochem.，357-376. 
Neuhaus, J.M•，and Rogers, J.C. (1998). Sorting of proteins to vacuoles in plant 
cells. Plant Molecular Biology 38, 127-144. 
Neuhaus, J.M., Pietrzak，M., and Boiler, T. (1994). Mutation analysis of the 
C-terminal vacuolar targeting peptide of tobacco chitinase: low specificity of 
the sorting system, and gradual transition between intracellular retention and 
secretion into the extracellular space. The Plant Journal 5，45-54. 
Neuhaus, J.M., Sticher, L., Meins, R, Jr., and Boiler, T. (1991). A short 
C-terminal sequence is necessary and sufficient for the targeting of chitinases 
to the plant vacuole. Proceedings of the National Academy of Sciences of the 
United States of America 88, 10362-10366. 
Okita, T.W., and Rogers, J.C. (1996). Compartmentation of Proteins in the 
Endomembrane System of Plant Cells. Annual Review of Plant Physiology 
and Plant Molecular Biology 47, 327-350. 
Paris, N., Rogers, S.W., Jiang, L., Kirsch, T” Beevers, L., Phillips, T.E., and 
Rogers, J.C. (1997). Molecular cloning and further characterization of a 
probable plant vacuolar sorting receptor. Plant Physiology 115, 29-39. 
Prince, W.S., McCormick, L.M., Wendt, D.J., Fitzpatrick, P.A., Schwartz, K.L., 
Aguilera, A.I., Koppaka, V., Christianson, T.M., Vellard, M.C., Pavloff, 
N., Lemontt, J.F., Qin, M.，Starr, C.M., Bu, G, and Zankel, T.C. (2004). 
Lipoprotein receptor binding, cellular uptake, and lysosomal delivery of 
fusions between the receptor-associated protein (RAP) and 
alpha-L-iduronidase or acid alpha-glucosidase. The Journal of Biological 
Chemistry 279’ 35037-35046. 
Robinson, D.G, Hinz, G, and Holstein, S.E. (1998). The molecular 
characterization of transport vesicles. Plant Molecular Biology 38, 49-76. 
Saalbach, G, Jung, R., Kunze, G, Saalbach, I., Adler, K.’ and Muntz, K. (1991). 
Different legumin protein domains act as vacuolar targeting signals. Plant 
108 
Cell 3，695-708. 
Sambrook, J., and Russell, D.W. (2001). Molecular cloning: a laboratory manual. 
Schillberg, S., Fischer, R., and Emans, N. (2003). Molecular farming of 
recombinant antibodies in plants. Cell and Molecular Life Science 60， 
433-445. 
Scott, H.S., Nelson, P.V., Hopwood, J.J., and Morris, C.P. (1991a). PCR of a 
Kpnl RFLP in the alpha-L-iduronidase (IDUA) gene. Nucleic Acids 
Research 19, 5796. 
Scott, H.S., Nelson, P.V., Litjens, T.，Hopwood, J.J., and Morris, C.P. (1993). 
Multiple polymorphisms within the alpha-L-iduronidase gene (IDUA): 
implications for a role in modification of MPS-I disease phenotype. Human 
Molecular Genetics 2，1471-1473. 
Scott, H.S., Bunge, S., Gal, A., Clarke, L.A., Morris, C.P., and Hopwood, J.J. 
(1995). Molecular genetics of mucopolysaccharidosis type I: diagnostic, 
clinical, and biological implications. Human Mutation 6, 288-302. 
Scott, H.S., Anson, D.S., Orsborn, A.M., Nelson, P.V., Clements, P.R., Morris, 
C.P., and Hopwood, J.J. (1991b). Human alpha-L-iduronidase: cDNA 
isolation and expression. Proceedings of the National Academy of Sciences 
of the United States of America 88, 9695-9699. 
Scott, H.S., Ashton, L.J., Eyre, H.J., Baker, E., Brooks, D.A., Callen, D.F., 
Sutherland, GR., Morris, C.P., and Hopwood, J.J. (1990). Chromosomal 
localization of the human alpha-L-iduronidase gene (IDUA) to 4pl6.3. 
American Journal of Human Genetics 47, 802-807. 
Seto, T.C. (2004). Membrane anchor for vacuolar targeting: expression of a human 
lysosomal enzyme iduronidase (hIDUA) in transgenic tobacco plants. 
(M.Phil, thesis, CUHK). 
Shimada, T., Kuroyanagi, M., Nishimura, M., and Hara-Nishimura, I. (1997). A 
pumpkin 72-kDa membrane protein of precursor-accumulating vesicles has 
characteristics of a vacuolar sorting receptor. Plant and Cell Physiology 38， 
1414-1420. 
Shull, R.M., Kakkis, E.D., McEntee, M.R, Kania, S.A., Jonas, A.J., and Neufeld, 
E.F. (1994). Enzyme replacement in a canine model of Hurler syndrome. 
Proceedings of the National Academy of Sciences of the United States of 
America 91, 12937-12941. 
Tse, Y.C., Mo, B., Hillmer, S•，Zhao, M.，Lo, S.W., Robinson, D.G, and Jiang, L. 
(2004). Identification of multivesicular bodies as prevacuolar compartments 
in Nicotiana tabacum BY-2 cells. Plant Cell 16, 672-693. 
Vitale, A., and Raikhel, N.V. (1999). What do proteins need to reach different 
vacuoles? Trends in Plant Science 4, 149-155. 
109 
Whitelam, GLC.，Cockburn, W.，and Owen, M.R. (1994). Antibody production in 
transgenic plants. Biochemical Society Transactions 22, 940-944. 
Zeitlin, L., Olmsted, S.S., Moench, T.R., Co, M.S., Martinell, B.J., Paradkar, 
V.M., Russell, D.R., Queen, C.，Cone, R.A., and Whaley, K.J. (1998). A 
humanized monoclonal antibody produced in transgenic plants for 
immunoprotection of the vagina against genital herpes. Nature 
Biotechnology 16, 1361-1364. 
Zhao, K.W., Faull, K.F., Kakkis, E.D., and Neufeld, E.F. (1997). Carbohydrate 
structures of recombinant human alpha-L-iduronidase secreted by Chinese 
hamster ovary cells. The Journal of Biological Chemistry 272，22758-22765. 
110 

C U H K L i b r a r i e s 
0 0 4 3 5 9 2 6 9 
